Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP9 | P14780 | 8/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.60 |
| ▸ | MMP2 | P08253 | 9/20 | 0.60 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | CTSL | P07711 | 1/20 | 0.57 |
| ▸ | CA2 | P00918 | 1/20 | 0.56 |
| ▸ | CA7 | P43166 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | MMP1 | P03956 | 1/20 | 0.54 |
| ▸ | MMP3 | P08254 | 1/20 | 0.54 |
| ▸ | MMP7 | P09237 | 1/20 | 0.54 |
| ▸ | MMP13 | P45452 | 1/20 | 0.54 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tpck SCHEMBL927265 | 1.00 | MMP9 (0.61) | MMP9TDP1MMP2ADAMTS4ALDH1A1 | |
| SCHEMBL669507 | 0.89 | MMP9 (0.60) | MMP9TDP1MMP2ADAMTS4ALDH1A1 | |
| SCHEMBL2213327 | 0.89 | MMP9 (0.60) | MMP9TDP1MMP2ADAMTS4ALDH1A1 | |
| SCHEMBL15213278 | 0.88 | MMP9 (0.63) | MMP9TDP1MMP2ADAMTS4ALDH1A1 | |
| SCHEMBL433895 | 0.88 | MMP9 (0.69) | MMP9TDP1MMP2ADAMTS4ALDH1A1 | |
| SCHEMBL1523717 | 0.88 | MMP9 (0.69) | MMP9TDP1MMP2ADAMTS4ALDH1A1 | |
| SCHEMBL31230483 | 0.87 | MMP9 (0.61) | MMP9TDP1MMP2ADAMTS4ALDH1A1 | |
| SCHEMBL628640 | 0.87 | MMP9 (0.64) | MMP9TDP1MMP2ADAMTS4ALDH1A1 | |
| SCHEMBL20601786 | 0.87 | MMP9 (0.64) | MMP9TDP1MMP2ADAMTS4ALDH1A1 | |
| Chloromethane SCHEMBL7649372 | 0.87 | MMP2 (0.75) | MMP9TDP1MMP2ADAMTS4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 487 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250281579-A1 | Methods and Compositions for Oral Administration of Proteins | ORAMED PHARMACEUTICALS INC (IL) | 2025-09-11 | — | — | US | claimed |
| US-20220160839-A1 | METHODS AND COMPOSITIONS FOR ORAL ADMINISTRATION OF PROTEINS | ORAMED PHARMACEUTICALS, INC. (IL) | 2022-05-26 | — | — | US | claimed |
| EP-2722054-B1 | Methods and compositions for oral administration of proteins | ORAMED PHARMACEUTICALS INC (IL) | 2018-03-21 | — | — | EP | claimed |
| US-20160206703-A1 | METHODS AND COMPOSITIONS FOR ORAL ADMINISTRATION OF PROTEINS | ORAMED PHARMACEUTICALS INC. (IL) | 2016-07-21 | — | — | US | claimed |
| US-9238674-B2 | Polynucleotide and polypeptide sequence and methods thereof | BIGTEC PRIVATE LIMITED (IN) | 2016-01-19 | — | — | US | claimed |
| EP-2722054-A1 | Methods and compositions for oral administration of proteins | Oramed Pharmaceuticals Inc. (IL) | 2014-04-23 | — | — | EP | claimed |
| US-8333985-B2 | Non-glycerol stabilized bone graft | WARSAW ORTHOPEDIC, INC. (US) | 2012-12-18 | — | — | US | claimed |
| EP-1933862-A2 | METHODS AND COMPOSITIONS FOR ORAL ADMINISTRATION OF PROTEINS | Oramed Pharmaceuticals Inc. (IL) | 2008-06-25 | — | — | EP | claimed |
| US-20070178158-A1 | Stabilized bone graft | WARSAW ORTHOPEDIC, INC. | 2007-08-02 | — | — | US | claimed |
| JP-2007519496-A | — | — | 2007-07-19 | — | — | JP | claimed |
| US-20070087957-A1 | Methods and compositions for oral administration of proteins | ORAMED PHARMACEUTICALS INC. (IL) | 2007-04-19 | — | — | US | claimed |
| WO-2007029238-A2 | METHODS AND COMPOSITIONS FOR ORAL ADMINISTRATION OF PROTEINS | ORAMED PHARMACEUTICALS, INC. (IL) | 2007-03-15 | — | — | WO | claimed |
| EP-1708651-A1 | STABILIZED BONE GRAFT | Osteotech, Inc., (US) | 2006-10-11 | — | — | EP | claimed |
| US-7071004-B1 | 14094, a novel human trypsin family member and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2006-07-04 | — | — | US | claimed |
| WO-2005072656-A1 | STABILIZED BONE GRAFT | OSTEOTECH, INC. (US) | 2005-08-11 | — | — | WO | claimed |
| EP-1434608-A2 | IMPROVED BONE GRAFT | Osteotech, Inc. (US) | 2004-07-07 | — | — | EP | claimed |
| EP-1420021-A1 | DNA Methyltransferase inhibitors | The Penn State Research Foundation (US) | 2004-05-19 | — | — | EP | claimed |
| US-20030143258-A1 | Bone graft | WARSAW ORTHOPEDIC, INC. | 2003-07-31 | — | — | US | claimed |
| WO-2003030956-A2 | IMPROVED BONE GRAFT | OSTEOTECH, INC. (US) | 2003-04-17 | — | — | WO | claimed |
| JP-6321804-A | — | — | None | — | — | JP | disclosed |
| US-20260124281-A1 | FORMULATIONS COMPRISING ACID-NEUTRALIZING POLYMER FOR ORAL ADMINISTRATION OF PARATHYROID HORMONE | ENTERA BIO LTD. (IL) | 2026-05-07 | — | — | US | disclosed |
| US-20260077011-A1 | INTEGRIN INHIBITORS AS THERAPY FOR OBESITY DISORDERS | UNIV RAMOT (IL) | 2026-03-19 | — | — | US | disclosed |
| US-20260071218-A1 | Oral Delivery of Antisense Conjugates Targeting PCSK9 | CIVI BIOPHARMA INC (US) | 2026-03-12 | — | — | US | disclosed |
| US-12559544-B2 | Antibodies that bind human metapneumovirus fusion protein and their use | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| US-20250388655-A1 | PEPTIDE CONSTRUCT HAVING A PROTEASE-CLEAVABLE LINKER | SORRISO PHARMACEUTICALS, INC. | 2025-12-25 | — | — | US | disclosed |
| US-12440833-B2 | Sample containers adapted for acoustic ejections and sample preservation and methods thereof | LABCYTE INC. (US) | 2025-10-14 | — | — | US | disclosed |
| US-20250281579-A1 | Methods and Compositions for Oral Administration of Proteins | ORAMED PHARMACEUTICALS INC (IL) | 2025-09-11 | — | — | US | disclosed |
| US-20250281396-A1 | METHODS AND COMPOSITIONS FOR ORAL ADMINISTRATION | ENTERA BIO LTD. (IL) | 2025-09-11 | — | — | US | disclosed |
| US-20250186554-A1 | FORMULATIONS COMPRISING ACID-NEUTRALIZING POLYMER FOR ORAL ADMINISTRATION OF GLUCAGON-LIKE PEPTIDE-1 AND ANALOGS THEREOF | ENTERA BIO LTD. (IL) | 2025-06-12 | — | — | US | disclosed |
| US-20250186558-A1 | FORMULATIONS COMPRISING ACID-NEUTRALIZING POLYMER FOR ORAL ADMINISTRATION OF ACTIVE AGENTS | ENTERA BIO LTD. (IL) | 2025-06-12 | — | — | US | disclosed |
| US-20250186555-A1 | FORMULATIONS COMPRISING ACID-NEUTRALIZING POLYMER FOR ORAL ADMINISTRATION OF GLUCAGON-LIKE PEPTIDE-2 | ENTERA BIO LTD. (IL) | 2025-06-12 | — | — | US | disclosed |
| US-20250188153-A1 | HMPV ANTIBODIES AND THEIR USE | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2025-06-12 | — | — | US | disclosed |
| US-20250186559-A1 | FORMULATIONS COMPRISING ACID-NEUTRALIZING POLYMER FOR ORAL ADMINISTRATION OF PARATHYROID HORMONE | ENTERA BIO LTD. (IL) | 2025-06-12 | — | — | US | disclosed |
| US-12311051-B2 | Methods and compositions for oral administration | ENTERA BIO LTD. (IL) | 2025-05-27 | — | — | US | disclosed |
| US-20250160367-A1 | ANTIVIRAL FEED COMPOSITION CONTAINING JAPANESE APRICOT JUICE AS ACTIVE INGREDIENT | BAEK IN HYEOK (KR) | 2025-05-22 | — | — | US | disclosed |
| US-12291708-B2 | Oral delivery of antisense conjugates targeting PCSK9 | CIVI BIOPHARMA, INC. (US) | 2025-05-06 | — | — | US | disclosed |
| EP-3256113-B1 | TREATMENT OF HYPOPARATHYROIDISM | ENTERA BIO LTD (IL) | 2025-04-02 | — | — | EP | disclosed |
| WO-2025046590-A1 | FORMULATIONS FOR ORAL ADMINISTRATION OF ACTIVE AGENTS | ENTERA BIO LTD. (IL) | 2025-03-06 | — | — | WO | disclosed |
| WO-2025046589-A1 | FORMULATIONS COMPRISING A COMBINATION OF ACID-NEUTRALIZING POLYMERIC AND NON-POLYMERIC SUBSTANCES FOR ORAL ADMINISTRATION OF ACTIVE AGENTS | ENTERA BIO LTD. (IL) | 2025-03-06 | — | — | WO | disclosed |
| EP-4514419-A1 | NON-IMMUNOGENIC TISSUE AUGMENTATION FORMULATION AND METHOD FOR FABRICATION | Board Of Trustees Of Michigan State University (US) | 2025-03-05 | — | — | EP | disclosed |
| US-12239691-B2 | Formulations for oral administration of active agents | ENTERA BIO LTD. (IL) | 2025-03-04 | — | — | US | disclosed |
| US-12234279-B2 | Peptide construct having a protease-cleavable linker | SORRISO PHARMACEUTICALS, INC. (US) | 2025-02-25 | — | — | US | disclosed |
| US-20250043231-A1 | APPARATUS AND METHOD FOR PERFORMING MICROORGANISM DETECTION | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED | 2025-02-06 | — | — | US | disclosed |
| EP-4482515-A1 | FORMULATIONS COMPRISING ACID-NEUTRALIZING POLYMER FOR ORAL ADMINISTRATION OF PARATHYROID HORMONE | Entera Bio Ltd. (IL) | 2025-01-01 | — | — | EP | disclosed |
| EP-4482513-A1 | FORMULATIONS COMPRISING ACID-NEUTRALIZING POLYMER FOR ORAL ADMINISTRATION OF GLUCAGON-LIKE PEPTIDE-2 | Entera Bio Ltd. (IL) | 2025-01-01 | — | — | EP | disclosed |
| EP-4482507-A1 | FORMULATIONS COMPRISING ACID-NEUTRALIZING POLYMER FOR ORAL ADMINISTRATION OF ACTIVE AGENTS | Entera Bio Ltd. (IL) | 2025-01-01 | — | — | EP | disclosed |
| EP-4482514-A1 | FORMULATIONS COMPRISING ACID-NEUTRALIZING POLYMER FOR ORAL ADMINISTRATION OF GLUCAGON-LIKE PEPTIDE-1 AND ANALOGS THEREOF | Entera Bio Ltd. (IL) | 2025-01-01 | — | — | EP | disclosed |
| US-20240424027-A1 | Anti-Aging Composition Using Mesenchymal Stem Cells and Methods Thereof | MECHANOGENIC K.K. (US) | 2024-12-26 | — | — | US | disclosed |
| US-20240415936-A1 | FORMULATIONS FOR ORAL ADMINISTRATION OF ACTIVE AGENTS | ENTERA BIO LTD. (IL) | 2024-12-19 | — | — | US | disclosed |
| US-20240398904-A1 | FORMULATIONS FOR ORAL ADMINISTRATION OF ACTIVE AGENTS | ENTERA BIO LTD. (IL) | 2024-12-05 | — | — | US | disclosed |
| US-12076373-B2 | Formulations for oral administration of active agents | ENTERA BIO LTD. (IL) | 2024-09-03 | — | — | US | disclosed |
| EP-4419913-A1 | SYSTEMS AND METHODS OF SIMPLE AND AUTOMATABLE PROTEIN DIGESTION USING MAGNETIC BEADS | Phenomenex, Inc. (US) | 2024-08-28 | — | — | EP | disclosed |
| US-12071610-B2 | Apparatus and method for performing microorganism detection | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2024-08-27 | — | — | US | disclosed |
| EP-4415730-A1 | ANTI-AGING COMPOSITION USING MESENCHYMAL STEM CELLS AND METHODS THEREOF | Mechanogenic K.K. (US) | 2024-08-21 | — | — | EP | disclosed |
| US-20240207409-A1 | ORAL DELIVERY OF OLIGONUCLEOTIDES | CIVI BIOPHARMA INC (US) | 2024-06-27 | — | — | US | disclosed |
| US-20240181020-A1 | TREATMENT OF HYPOPARATHYROIDISM | ENTERA BIO LTD. (IL) | 2024-06-06 | — | — | US | disclosed |
| EP-4333875-A1 | ALPHA-1-ANTITRYPSIN (AAT) IN THE TREATMENT AND/OR PREVENTION OF NEUROLOGICAL DISORDERS | Ageronix SA (CH) | 2024-03-13 | — | — | EP | disclosed |
| WO-2024047655-A1 | INTEGRIN INHIBITORS AS THERAPY FOR METABOLIC DISORDERS | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2024-03-07 | — | — | WO | disclosed |
| US-20240067965-A1 | ORAL DELIVERY OF ANTISENSE CONJUGATES TARGETING PCSK9 | CIVI BIOPHARMA INC (US) | 2024-02-29 | — | — | US | disclosed |
| EP-4326329-A1 | ORAL DELIVERY OF OLIGONUCLEOTIDES | Civi Biopharma, Inc. (US) | 2024-02-28 | — | — | EP | disclosed |
| WO-2023211931-A1 | NON-IMMUNOGENIC TISSUE AUGMENTATION FORMULATION AND METHOD FOR FABRICATION | BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY (US) | 2023-11-02 | — | — | WO | disclosed |
| EP-4259799-A1 | ORAL DELIVERY OF ANTISENSE CONJUGATES TARGETING PCSK9 | Civi Biopharma, Inc. (US) | 2023-10-18 | — | — | EP | disclosed |
| WO-2023161933-A1 | FORMULATIONS COMPRISING ACID-NEUTRALIZING POLYMER FOR ORAL ADMINISTRATION OF PARATHYROID HORMONE | ENTERA BIO LTD. (IL) | 2023-08-31 | — | — | WO | disclosed |
| WO-2023161936-A1 | FORMULATIONS COMPRISING ACID-NEUTRALIZING POLYMER FOR ORAL ADMINISTRATION OF GROWTH HORMONE-RELEASING HORMONE | ENTERA BIO LTD. (IL) | 2023-08-31 | — | — | WO | disclosed |
| WO-2023161937-A1 | FORMULATIONS COMPRISING ACID-NEUTRALIZING POLYMER FOR ORAL ADMINISTRATION OF GLUCAGON-LIKE PEPTIDE-2 | ENTERA BIO LTD. (IL) | 2023-08-31 | — | — | WO | disclosed |
| WO-2023161938-A1 | FORMULATIONS COMPRISING ACID-NEUTRALIZING POLYMER FOR ORAL ADMINISTRATION OF KAPPA OPIOID RECEPTOR AGONIST PEPTIDE | ENTERA BIO LTD. (IL) | 2023-08-31 | — | — | WO | disclosed |
| WO-2023161935-A1 | FORMULATIONS COMPRISING ACID-NEUTRALIZING POLYMER FOR ORAL ADMINISTRATION OF GROWTH HORMONE | ENTERA BIO LTD. (IL) | 2023-08-31 | — | — | WO | disclosed |
| WO-2023161939-A1 | FORMULATIONS COMPRISING ACID-NEUTRALIZING POLYMER FOR ORAL ADMINISTRATION OF GLUCAGON-LIKE PEPTIDE-1 AND ANALOGS THEREOF | ENTERA BIO LTD. (IL) | 2023-08-31 | — | — | WO | disclosed |
| WO-2023161934-A1 | FORMULATIONS COMPRISING ACID-NEUTRALIZING POLYMER FOR ORAL ADMINISTRATION OF ACTIVE AGENTS | ENTERA BIO LTD. (IL) | 2023-08-31 | — | — | WO | disclosed |
| US-20230240997-A1 | METHOD OF TREATING CANCER | THERASYN SENSORS INC (US) | 2023-08-03 | — | — | US | disclosed |
| US-11707505-B2 | VCP and factor H as viral entry inhibitors | KING FAISAL SPECIALIST HOSPITAL & RESEARCH CENTRE (SA) | 2023-07-25 | — | — | US | disclosed |
| EP-4188415-A2 | NEUROPILIN AND ANGIOTENSIN CONVERTING ENZYME 2 FUSION PEPTIDES FOR TREATING VIRAL INFECTIONS | Pinetree Therapeutics, Inc. (US) | 2023-06-07 | — | — | EP | disclosed |
| US-20230168259-A1 | METHOD FOR PREDICTING THE COURSE OF A VIRAL DISEASE | LEIBNIZ-INSTITUT FÜR VIROLOGIE (DE) | 2023-06-01 | — | — | US | disclosed |
| US-11660327-B2 | Methods and compositions for oral administration of proteins | ORAMED LTD. (IL) | 2023-05-30 | — | — | US | disclosed |
| WO-2023069992-A1 | SYSTEMS AND METHODS OF SIMPLE AND AUTOMATABLE PROTEIN DIGESTION USING MAGNETIC BEADS | PHENOMENEX, INC. (US) | 2023-04-27 | — | — | WO | disclosed |
| WO-2023064404-A1 | ANTI-AGING COMPOSITION USING MESENCHYMAL STEM CELLS AND METHODS THEREOF | MECHANOGENIC K.K. (US) | 2023-04-20 | — | — | WO | disclosed |
| US-20230085439-A1 | ANTIBODIES THAT BIND HUMAN METAPNEUMOVIRUS FUSION PROTEIN AND THEIR USE | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2023-03-16 | — | — | US | disclosed |
| EP-4143580-A1 | METHOD FOR PREDICTING THE COURSE OF A VIRAL DISEASE | Leibniz-Institut für Virologie (DE) | 2023-03-08 | — | — | EP | disclosed |
| EP-4142775-A1 | TREATMENT AND/OR PREVENTION OF A DISEASE OR A SYNDROME RELATED TO A VIRUS INFECTION | Atlas Biotechnology S.A. (CH) | 2023-03-08 | — | — | EP | disclosed |
| US-11564964-B2 | Compositions and methods for the treatment of coronavirus infection | KING ABDULAZIZ UNIVERSITY (SA) | 2023-01-31 | — | — | US | disclosed |
| US-20220380761-A1 | ORAL DELIVERY OF OLIGONUCLEOTIDES | CIVI BIOPHARMA, INC. (US) | 2022-12-01 | — | — | US | disclosed |
| US-20220348960-A1 | VIRAL MEDIATED GENE DELIVERY FOR TRANSIENT EXPRESSION OF PROTEINS | REGENTS OF THE UNIVERSITY OF MINNESOTA | 2022-11-03 | — | — | US | disclosed |
| WO-2022226217-A1 | ORAL DELIVERY OF OLIGONUCLEOTIDES | CIVI BIOPHARMA, INC. (US) | 2022-10-27 | — | — | WO | disclosed |
| WO-2022189679-A1 | ALPHA-1-ANTITRYPSIN (AAT) IN THE TREATMENT AND/OR PREVENTION OF NEUROLOGICAL DISORDERS | ATLAS BIOTECHNOLOGY S.A. (CH) | 2022-09-15 | — | — | WO | disclosed |
| US-20220265746-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CORONAVIRUS INFECTION | KING ABDULAZIZ UNIVERSITY (SA) | 2022-08-25 | — | — | US | disclosed |
| EP-4041216-A1 | ANTIVIRAL COMPOUNDS AND METHODS | The University of Nottingham (GB) | 2022-08-17 | — | — | EP | disclosed |
| US-11400062-B2 | Compositions comprising enzyme-cleavable amphetamine prodrugs and inhibitors thereof | SIGNATURE THERAPEUTICS, INC. (US) | 2022-08-02 | — | — | US | disclosed |
| EP-4025240-A1 | IL-22 ORAL, INTRA-RECTAL, OR OTHER GUT-RELATED COMPOSITIONS AND METHODS OF USE THEREOF | Amgen Inc. (US) | 2022-07-13 | — | — | EP | disclosed |
| US-20220213476-A1 | ORAL DELIVERY OF ANTISENSE CONJUGATES TARGETING PCSK9 | CIVI BIOPHARMA, INC. (US) | 2022-07-07 | — | — | US | disclosed |
| EP-4021435-A1 | COMBINATIONS OF MEK INHIBITORS WITH CAP-DEPENDENT ENDONUCLEASE INHIBITORS | Atriva Therapeutics GmbH (DE) | 2022-07-06 | — | — | EP | disclosed |
| US-20220204971-A1 | Compositions and Methods for Inhibiting Cancers and Viruses | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2022-06-30 | — | — | US | disclosed |
| WO-2022125913-A1 | ORAL DELIVERY OF ANTISENSE CONJUGATES TARGETING PCSK9 | CIVI BIOPHARMA, INC. (US) | 2022-06-16 | — | — | WO | disclosed |
| US-20220151919-A1 | METHODS AND COMPOSITIONS FOR ORAL ADMINISTRATION | ENTERA BIO LTD. (IL) | 2022-05-19 | — | — | US | disclosed |
| WO-2022026943-A9 | NEUROPILIN AND ANGIOTENSIN CONVERTING ENZYME 2 FUSION PEPTIDES FOR TREATING VIRAL INFECTIONS | PINETREE THERAPEUTICS, INC. (US) | 2022-03-03 | — | — | WO | disclosed |
| US-20220054479-A1 | OPIOID COMPOSITIONS RESISTANT TO OVERDOSE AND ABUSE | ELYSIUM THERAPEUTICS, INC. | 2022-02-24 | — | — | US | disclosed |
| US-11246827-B2 | Methods and compositions for oral administration | ENTERA BIO LTD. (IL) | 2022-02-15 | — | — | US | disclosed |
| US-11179355-B2 | Compositions comprising enzyme-cleavable amphetamine prodrugs and inhibitors thereof | SIGNATURE THERAPEUTICS, INC. (US) | 2021-11-23 | — | — | US | disclosed |
| WO-2021219873-A1 | METHOD FOR PREDICTING THE COURSE OF A VIRAL DISEASE | Heinrich-Pette-Institut Leibniz-Institut für experimentelle Virologie (DE) | 2021-11-04 | — | — | WO | disclosed |
| US-11154549-B2 | Opioid compositions resistant to overdose and abuse | ELYSIUM THERAPEUTICS, INC. (US) | 2021-10-26 | — | — | US | disclosed |
| US-20210322305-A1 | Methods and Compositions for Oral Administration of Exenatide | ORAMED LTD. (IL) | 2021-10-21 | — | — | US | disclosed |
| US-11083190-B2 | Soft gel systems in modulating stem cell development | FUNAKI, MAKOTO | 2021-08-10 | — | — | US | disclosed |
| EP-2702388-B1 | SAMPLE CONTAINERS ADAPTED FOR ACOUSTIC EJECTIONS AND SAMPLE PRESERVATION AND METHODS THEREOF | LABCYTE INC (US) | 2021-08-04 | — | — | EP | disclosed |
| US-20210230533-A1 | APPARATUS AND METHOD FOR PERFORMING MICROORGANISM DETECTION | NATIONAL SCIENCE FOUNDATION | 2021-07-29 | — | — | US | disclosed |
| US-20210198345-A1 | PEPTIDE CONSTRUCT HAVING A PROTEASE-CLEAVABLE LINKER | SORRISO PHARMACEUTICALS, INC. | 2021-07-01 | — | — | US | disclosed |
| US-11028408-B2 | Recombinant influenza viruses and constructs and uses thereof | UNIVERSITY OF MARYLAND, COLLEGE PARK (US) | 2021-06-08 | — | — | US | disclosed |
| EP-3827081-A2 | COMPOSITIONS AND METHODS FOR INHIBITING CANCERS AND VIRUSES | Icahn School of Medicine at Mount Sinai (US) | 2021-06-02 | — | — | EP | disclosed |
| US-11013796-B2 | Porcine parainfluenza virus type 1 isolates and immunogenic compositions therefrom | IOWA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2021-05-25 | — | — | US | disclosed |
| US-20210145935-A1 | VCP AND FACTOR H AS VIRAL ENTRY INHIBITORS | KING FAISAL SPECIALIST HOSPITAL & RESEARCH CENTRE (SA) | 2021-05-20 | — | — | US | disclosed |
| EP-3821948-A1 | VCP AND FACTOR H AS VIRAL ENTRY INHIBITORS | King Faisal Specialist Hospital & Research Centre (SA) | 2021-05-19 | — | — | EP | disclosed |
| US-20210113663-A1 | Methods and Compositions for Oral Administration of Proteins | ORAMED LTD. (IL) | 2021-04-22 | — | — | US | disclosed |
| WO-2021046133-A1 | IL-22 ORAL, INTRA-RECTAL, OR OTHER GUT-RELATED COMPOSITIONS AND METHODS OF USE THEREOF | AMGEN INC. (US) | 2021-03-11 | — | — | WO | disclosed |
| WO-2021037956-A1 | COMBINATIONS OF MEK INHIBITORS WITH CAP-DEPENDENT ENDONUCLEASE INHIBITORS | ATRIVA THERAPEUTICS GMBH (DE) | 2021-03-04 | — | — | WO | disclosed |
| EP-3777831-A1 | METHODS AND COMPOSITIONS FOR ORAL ADMINISTRATION OF PROTEINS | Oramed Ltd. (IL) | 2021-02-17 | — | — | EP | disclosed |
| EP-2683394-B1 | ACTIVE AGENT PRODRUGS WITH HETEROCYCLIC LINKERS | SIGNATURE THERAPEUTICS INC (US) | 2021-01-06 | — | — | EP | disclosed |
| US-10881714-B2 | Methods and compositions for oral administration of proteins | ORAMED LTD. (IL) | 2021-01-05 | — | — | US | disclosed |
| EP-3741359-A1 | METHODS AND COMPOSITIONS FOR ORAL ADMINISTRATION OF PROTEINS | Entera Bio Ltd. (IL) | 2020-11-25 | — | — | EP | disclosed |
| US-10781472-B2 | Systems and methods for determining cyclic nucleotide concentration and related pathway activation | PROMEGA CORPORATION (US) | 2020-09-22 | — | — | US | disclosed |
| US-20200253900-A1 | Compositions Comprising Enzyme-Cleavable Amphetamine Prodrugs and Inhibitors Thereof | 3I, LP | 2020-08-13 | — | — | US | disclosed |
| EP-2331072-B1 | METHODS AND COMPOSITIONS FOR ORAL ADMINISTRATION OF PROTEINS | ENTERA BIO LTD (IL) | 2020-07-22 | — | — | EP | disclosed |
| US-20200138913-A1 | FORMULATIONS FOR ORAL ADMINISTRATION OF ACTIVE AGENTS | ENTERA BIO LTD. (IL) | 2020-05-07 | — | — | US | disclosed |
| US-20200093817-A1 | OPIOID COMPOSITIONS RESISTANT TO OVERDOSE AND ABUSE | ELYSIUM THERAPEUTICS, INC. | 2020-03-26 | — | — | US | disclosed |
| US-10583177-B2 | Formulations for oral administration of active agents | ENTERA BIO LTD. (IL) | 2020-03-10 | — | — | US | disclosed |
| US-20200069789-A1 | NOVEL PORCINE PARAINFLUENZA VIRUS TYPE 1 ISOLATES AND IMMUNOGENIC COMPOSITIONS THEREFROM | IOWA STATE UNIVERSITY RESEARCH FOUNDATION, INC. | 2020-03-05 | — | — | US | disclosed |
| US-10577639-B2 | Rapid bed-side measurement of neutrophil elastase activity in biological fluids | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2020-03-03 | — | — | US | disclosed |
| WO-2020028559-A1 | APPARATUS AND METHOD FOR PERFORMING MICROORGANISM DETECTION | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION (US) | 2020-02-06 | — | — | WO | disclosed |
| WO-2020023776-A2 | COMPOSITIONS AND METHODS FOR INHIBITING CANCERS AND VIRUSES | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2020-01-30 | — | — | WO | disclosed |
| US-20190314275-A1 | Methods and Compositions for Rectal Administration of Exenatide | ORAMED LTD. (IL) | 2019-10-17 | — | — | US | disclosed |
| EP-2403447-B1 | MICROENCAPSULATED BIOACTIVE AGENTS FOR ORAL DELIVERY AND METHODS OF USE THEREOF | TAMARISK TECH GROUP LLC (US) | 2019-10-16 | — | — | EP | disclosed |
| US-10420721-B2 | Methods and compositions for oral administration | ENTERA BIO LTD. (IL) | 2019-09-24 | — | — | US | disclosed |
| US-20190247312-A1 | PHARMACEUTICAL PREPARATION FOR DELIVERY OF PEPTIDES AND PROTEINS | TAMARISK TECHNOLOGIES GROUP LLC | 2019-08-15 | — | — | US | disclosed |
| US-20190225935-A1 | Low Rigidity Gels for MSC Growth Modulation | Funaki, Makoto (US) | 2019-07-25 | — | — | US | disclosed |
| US-10357511-B2 | Bone matrix compositions and methods | WARSAW ORTHOPEDIC, INC. (US) | 2019-07-23 | — | — | US | disclosed |
| US-10350162-B2 | Methods and compositions for oral administration of exenatide | ORAMED LTD. (IL) | 2019-07-16 | — | — | US | disclosed |
| US-20190209657-A1 | FORMULATIONS FOR ORAL ADMINISTRATION OF ACTIVE AGENTS | ENTERA BIO LTD. (IL) | 2019-07-11 | — | — | US | disclosed |
| US-10335406-B2 | Opioid compositions resistant to overdose and abuse | ELYSIUM THERAPEUTICS, INC. (US) | 2019-07-02 | — | — | US | disclosed |
| EP-3500291-A1 | FORMULATIONS FOR ORAL ADMINISTRATION OF ACTIVE AGENTS | Entera Bio Ltd. (IL) | 2019-06-26 | — | — | EP | disclosed |
| US-10328179-B2 | Bone matrix compositions and methods | WARSAW ORTHOPEDIC, INC. (US) | 2019-06-25 | — | — | US | disclosed |
| US-20190175507-A1 | COMPOSITIONS FOR ORAL ADMINISTRATION OF ACTIVE AGENTS | TAMARISK TECHNOLOGIES GROUP LLC | 2019-06-13 | — | — | US | disclosed |
| US-20190175515-A1 | CHOLESTERYL ESTER VESICLES LOADING PEPTIDES, PROTEINS AND NUCLEIC ACIDS INTO CHYLOMICRONS AND BODY CELLS | THERASYN SENSORS, INC. | 2019-06-13 | — | — | US | disclosed |
| EP-3474826-A1 | PHARMACEUTICAL PREPARATION FOR DELIVERY OF PEPTIDES AND PROTEINS | Tamarisk Technologies Group, LLC (US) | 2019-05-01 | — | — | EP | disclosed |
| US-20180369339-A1 | Methods and Compositions for Oral Administration of Proteins | ORAMED LTD. (IL) | 2018-12-27 | — | — | US | disclosed |
| US-20180340210-A1 | METHODS FOR CYCLIC NUCLEOTIDE DETERMINATION | JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT | 2018-11-29 | — | — | US | disclosed |
| EP-2560486-B1 | COMPOSITIONS COMPRISING ENZYME-CLEAVABLE AMPHETAMINE PRODRUGS AND INHIBITORS THEREOF | SIGNATURE THERAPEUTICS INC (US) | 2018-11-21 | — | — | EP | disclosed |
| US-20180304251-A1 | SAMPLE CONTAINERS ADAPTED FOR ACOUSTIC EJECTIONS AND SAMPLE PRESERVATION AND METHODS THEREOF | LABCYTE INC. | 2018-10-25 | — | — | US | disclosed |
| US-20180280292-A1 | METHODS AND COMPOSITIONS FOR ORAL ADMINISTRATION | ENTERA BIO LTD. (IL) | 2018-10-04 | — | — | US | disclosed |
| US-10058593-B2 | Methods and compositions for oral administration of proteins | ORAMED LTD. (IL) | 2018-08-28 | — | — | US | disclosed |
| EP-1434608-B1 | IMPROVED BONE GRAFT | WARSAW ORTHOPEDIC INC (US) | 2018-08-22 | — | — | EP | disclosed |
| US-10016757-B2 | Sample containers adapted for acoustic ejections and sample preservation and methods thereof | LABCYTE INC. (US) | 2018-07-10 | — | — | US | disclosed |
| US-10010503-B2 | Methods and compositions for oral administration | ENTERA BIO LTD. (IL) | 2018-07-03 | — | — | US | disclosed |
| US-10000792-B2 | Methods for cyclic nucleotide determination | PROMEGA CORPORATION (US) | 2018-06-19 | — | — | US | disclosed |
| US-9949945-B2 | 3′ equatorial-fluorine-substituted neuraminidase inhibitor compounds, compositions and methods for the use thereof as anti-virals | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2018-04-24 | — | — | US | disclosed |
| EP-2509595-B1 | INHIBITORS OF HEMOPOIETIC CELL KINASE (P59-HCK) AND THEIR USE IN THE TREATMENT OF INFLUENZA INFECTION | RESPIVERT LTD (GB) | 2018-04-11 | — | — | EP | disclosed |
| US-20180085366-A1 | OPIOID COMPOSITIONS RESISTANT TO OVERDOSE AND ABUSE | ELYSIUM THERAPEUTICS, INC. | 2018-03-29 | — | — | US | disclosed |
| EP-2722054-B1 | Methods and compositions for oral administration of proteins | ORAMED PHARMACEUTICALS INC (IL) | 2018-03-21 | — | — | EP | disclosed |
| US-20180050096-A1 | TREATMENT OF HYPOPARATHYROIDISM | ENTERA BIO LTD. (IL) | 2018-02-22 | — | — | US | disclosed |
| WO-2018033927-A1 | FORMULATIONS FOR ORAL ADMINISTRATION OF ACTIVE AGENTS | ENTERA BIO LTD. (IL) | 2018-02-22 | — | — | WO | disclosed |
| US-20180036234-A1 | TREATMENT OF BONE FRACTURES AND DEFECTS | ENTERA BIO LTD. (IL) | 2018-02-08 | — | — | US | disclosed |
| US-20180037639-A1 | PEPTIDE CONSTRUCT HAVING A PROTEASE-CLEAVABLE LINKER | VHSQUARED LIMITED (GB) | 2018-02-08 | — | — | US | disclosed |
| US-20180036382-A1 | FORMULATIONS FOR ORAL ADMINISTRATION OF ACTIVE AGENTS WITH CONTROLLED ABSORPTION PROFILE | ENTERA BIO LTD. (IL) | 2018-02-08 | — | — | US | disclosed |
| EP-3277317-A1 | PEPTIDE CONSTRUCT HAVING A PROTEASE-CLEAVABLE LINKER | VHsquared Limited (GB) | 2018-02-07 | — | — | EP | disclosed |
| US-20180028622-A1 | TREATMENT OF OSTEOPOROSIS | ENTERA BIO LTD. (IL) | 2018-02-01 | — | — | US | disclosed |
| EP-3275460-A1 | METHODS AND COMPOSITIONS FOR ORAL ADMINISTRATION OF EXENATIDE | Oramed Ltd. (IL) | 2018-01-31 | — | — | EP | disclosed |
| US-20180021272-A1 | FORMULATIONS FOR ORAL ADMINISTRATION OF ACTIVE AGENTS | ENTERA BIO LTD. (IL) | 2018-01-25 | — | — | US | disclosed |
| US-20180000830-A1 | INHIBITORS OF HEMOPOIETIC CELL KINASE (P-59-HCK) AND THEIR USE IN THE TREATMENT OF INFLUENZA INFECTION | RESPIVERT LIMITED (GB) | 2018-01-04 | — | — | US | disclosed |
| WO-2018005518-A1 | PHARMACEUTICAL PREPARATION FOR DELIVERY OF PEPTIDES AND PROTEINS | TAMARISK TECHNOLOGIES GROUP LLC (US) | 2018-01-04 | — | — | WO | disclosed |
| EP-3256153-A1 | FORMULATIONS FOR ORAL ADMINISTRATION OF ACTIVE AGENTS WITH CONTROLLED ABSORPTION PROFILE | Entera Bio Ltd. (IL) | 2017-12-20 | — | — | EP | disclosed |
| EP-3256152-A1 | TREATMENT OF BONE FRACTURES AND DEFECTS | Entera Bio Ltd. (IL) | 2017-12-20 | — | — | EP | disclosed |
| EP-3256114-A1 | TREATMENT OF OSTEOPOROSIS | Entera Bio Ltd. (IL) | 2017-12-20 | — | — | EP | disclosed |
| EP-3256149-A1 | FORMULATIONS FOR ORAL ADMINISTRATION OF ACTIVE AGENTS | Entera Bio Ltd. (IL) | 2017-12-20 | — | — | EP | disclosed |
| EP-3256113-A1 | TREATMENT OF HYPOPARATHYROIDISM | Entera Bio Ltd. (IL) | 2017-12-20 | — | — | EP | disclosed |
| US-9840532-B2 | 5′-substituted nucleoside compounds | ELI LILLY AND COMPANY (US) | 2017-12-12 | — | — | US | disclosed |
| WO-2017210543-A1 | COMPOSITIONS FOR ORAL ADMINISTRATION OF ACTIVE AGENTS | TAMARISK TECHNOLOGIES GROUP LLC (US) | 2017-12-07 | — | — | WO | disclosed |
| US-20170296581-A1 | BONE MATRIX COMPOSITIONS AND METHODS | WARSAW ORTHOPEDIC INC (US) | 2017-10-19 | — | — | US | disclosed |
| EP-2300031-B1 | METHODS AND COMPOSITIONS FOR ORAL ADMINISTRATION OF EXENATIDE | ORAMED LTD (IL) | 2017-09-20 | — | — | EP | disclosed |
| EP-3207948-A1 | BONE MATRIX COMPOSITIONS AND METHODS | Warsaw Orthopedic, Inc. (US) | 2017-08-23 | — | — | EP | disclosed |
| US-9717822-B2 | Bone matrix compositions and methods | WARSAW ORTHOPEDIC, INC. (US) | 2017-08-01 | — | — | US | disclosed |
| US-20170165223-A1 | 3' Equatorial-Fluorine-Substituted Neuraminidase Inhibitor Compounds, Compositions and Methods for the Use Thereof as Anti-Virals | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2017-06-15 | — | — | US | disclosed |
| US-9637465-B2 | 3′ Equatorial-fluorine-substituted neuraminidase inhibitor compounds, compositions and methods for the use thereof as anti-virals | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2017-05-02 | — | — | US | disclosed |
| EP-2167147-B1 | BONE MATRIX COMPOSITIONS AND METHODS | WARSAW ORTHOPEDIC INC (US) | 2017-03-29 | — | — | EP | disclosed |
| US-9585963-B2 | Compositions comprising enzyme-cleavable opioid prodrugs and inhibitors thereof | SIGNATURE THERAPEUTICS, INC. (US) | 2017-03-07 | — | — | US | disclosed |
| EP-2295088-B1 | Improved bone graft | WARSAW ORTHOPEDIC INC (US) | 2016-12-07 | — | — | EP | disclosed |
| US-20160326208-A1 | 5'-SUBSTITUTED NUCLEOSIDE COMPOUNDS | ELI LILLY AND COMPANY | 2016-11-10 | — | — | US | disclosed |
| WO-2016156466-A1 | PEPTIDE CONSTRUCT HAVING A PROTEASE-CLEAVABLE LINKER | VHSQUARED LIMITED (GB) | 2016-10-06 | — | — | WO | disclosed |
| US-9421243-B2 | Therapy for influenza like illness | SYNAIRGEN RESEARCH LIMITED (GB) | 2016-08-23 | — | — | US | disclosed |
| US-20160235694-A1 | Compositions Comprising Enzyme-Cleavable Amphetamine Prodrugs and Inhibitors Thereof | 3I, LP | 2016-08-18 | — | — | US | disclosed |
| WO-2016128971-A1 | TREATMENT OF BONE FRACTURES AND DEFECTS | ENTERA BIO LTD. (IL) | 2016-08-18 | — | — | WO | disclosed |
| WO-2016128970-A1 | TREATMENT OF HYPOPARATHYROIDISM | ENTERA BIO LTD. (IL) | 2016-08-18 | — | — | WO | disclosed |
| WO-2016128974-A1 | FORMULATIONS FOR ORAL ADMINISTRATION OF ACTIVE AGENTS | ENTERA BIO LTD. (IL) | 2016-08-18 | — | — | WO | disclosed |
| WO-2016128973-A1 | TREATMENT OF OSTEOPOROSIS | ENTERA BIO LTD. (IL) | 2016-08-18 | — | — | WO | disclosed |
| WO-2016128972-A1 | FORMULATIONS FOR ORAL ADMINISTRATION OF ACTIVE AGENTS WITH CONTROLLED ABSORPTION PROFILE | ENTERA BIO LTD. (IL) | 2016-08-18 | — | — | WO | disclosed |
| US-9415136-B2 | Osteoinductive demineralized cancellous bone | WARSAW ORTHOPEDIC, INC. (US) | 2016-08-16 | — | — | US | disclosed |
| US-9402877-B2 | Methods and compositions for oral administration of melanocortin receptor agonist compounds | BAR-CHAMA, NATAN, MR | 2016-08-02 | — | — | US | disclosed |
| WO-2016118489-A1 | COMBINED ANALYSIS OF SMALL MOLECULES AND PROTEINS BY MASS SPECTROMETRY | SISCAPA ASSAY TECHNOLOGIES, INC. (US) | 2016-07-28 | — | — | WO | disclosed |
| US-20160206703-A1 | METHODS AND COMPOSITIONS FOR ORAL ADMINISTRATION OF PROTEINS | ORAMED PHARMACEUTICALS INC. (IL) | 2016-07-21 | — | — | US | disclosed |
| EP-3034606-A1 | LOW RIGIDITY GELS FOR MSC GROWTH MODULATION | Funaki, Makoto (US) | 2016-06-22 | — | — | EP | disclosed |
| US-20160144075-A1 | BONE MATRIX COMPOSITIONS AND METHODS | WARSAW ORTHOPEDIC INC (US) | 2016-05-26 | — | — | US | disclosed |
| EP-2173864-B1 | LOW RIGIDITY GELS FOR MSC GROWTH MODULATION | FUNAKI MAKOTO (US) | 2016-05-11 | — | — | EP | disclosed |
| EP-2173859-B1 | SOFT GEL SYSTEMS IN MODULATING STEM CELL DEVELOPMENT | FUNAKI MAKOTO (US) | 2016-05-11 | — | — | EP | disclosed |
| US-9278077-B2 | Microencapsulated bioactive agents for oral delivery and methods of use thereof | TAMARISK TECHNOLOGIES GROUP, LLC (US) | 2016-03-08 | — | — | US | disclosed |
| US-20160058699-A1 | METHODS AND COMPOSITIONS FOR ORAL ADMINISTRATION OF INSULIN | ENTERA BIO LTD. (IL) | 2016-03-03 | — | — | US | disclosed |
| US-20160045512-A1 | Inhibitors of Hemopoietic Cell Kinase (P59-HCK) and Their Use in the Treatment of Influenza Infection | RESPIVERT LIMITED (GB) | 2016-02-18 | — | — | US | disclosed |
| US-9259456-B2 | Methods and compositions for oral administration of proteins | ORAMED PHARMACEUTICALS INC. (IL) | 2016-02-16 | — | — | US | disclosed |
| US-20160002291-A1 | Active Agent Prodrugs with Heterocyclic Linkers | SIGNATURE THERAPEUTICS INC (US) | 2016-01-07 | — | — | US | disclosed |
| US-9205122-B2 | Herbal composition comprising ginger and goldenrod for the treatment of cold and flu | MARESINS PHARMA, INC. (CA) | 2015-12-08 | — | — | US | disclosed |
| US-9186412-B2 | Methods and compositions for oral administration of insulin | ENTERA BIO LTD. (IL) | 2015-11-17 | — | — | US | disclosed |
| US-20150297736-A1 | Compositions Comprising Enzyme-Cleavable Opioid Prodrugs and Inhibitors Thereof | 3I, LP | 2015-10-22 | — | — | US | disclosed |
| US-9162012-B2 | Bone matrix compositions and methods | WARSAW ORTHOPEDIC, INC. (US) | 2015-10-20 | — | — | US | disclosed |
| US-9139612-B2 | Active agent prodrugs with heterocyclic linkers | SIGNATURE THERAPEUTICS, INC. (US) | 2015-09-22 | — | — | US | disclosed |
| US-9133267-B2 | Antibody treatment of Alzheimer's and related diseases | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2015-09-15 | — | — | US | disclosed |
| EP-2490703-B1 | HERBAL COMPOSITION COMPRISING GINGER AND GOLDENROD FOR THE TREATMENT OF INFLUENZA INFECTION | MARESINS PHARMA INC (CA) | 2015-09-09 | — | — | EP | disclosed |
| US-9125952-B2 | Immunostimulatory compositions comprising liposome-encapsulated oligonucleotides and epitopes | INDUSTRY ACADEMIC COOPERATION FOUNDATION, HALLYM UNIVERSITY (KR) | 2015-09-08 | — | — | US | disclosed |
| US-9101653-B2 | Influenza viruses with mutant PB2 gene segment as live attenuated vaccines | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2015-08-11 | — | — | US | disclosed |
| US-9095627-B2 | Opioid prodrugs with heterocyclic linkers | SIGNATURE THERAPEUTICS, INC. (US) | 2015-08-04 | — | — | US | disclosed |
| US-20150196625-A9 | Metal Sensitive Mutants of Matrix Metalloproteases and uses thereof | HALOZYME THERAPEUTICS, INC. | 2015-07-16 | — | — | US | disclosed |
| US-20150190547-A1 | BONE MATRIX COMPOSITIONS AND METHODS | WARSAW ORTHOPEDIC INC (US) | 2015-07-09 | — | — | US | disclosed |
| US-9040032-B2 | Compositions comprising enzyme-cleavable opioid prodrugs and inhibitors thereof | SIGNATURE THERAPEUTICS, INC. (US) | 2015-05-26 | — | — | US | disclosed |
| US-8992965-B2 | Bone matrix compositions and methods | WARSAW ORTHOPEDIC, INC. (US) | 2015-03-31 | — | — | US | disclosed |
| US-20150037376-A1 | METHODS AND COMPOSITIONS FOR ORAL ADMINISTRATION OF MELANOCORTIN RECEPTOR AGONIST COMPOUNDS | SETH, GAURAV, MR | 2015-02-05 | — | — | US | disclosed |
| US-8911759-B2 | Bone matrix compositions and methods | WARSAW ORTHOPEDIC, INC. (US) | 2014-12-16 | — | — | US | disclosed |
| US-20140350095-A1 | 3' Equatorial-Fluorine-Substituted Neuraminidase Inhibitor Compounds, Compositions and Methods for the Use Thereof as Anti-Virals | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2014-11-27 | — | — | US | disclosed |
| US-20140348906-A1 | IMMUNOSTIMULATORY COMPOSITIONS COMPRISING LIPOSOME-ENCAPSULATED OLIGONUCLEOTIDES AND EPITOPES | PEPTRON, INC. (KR) | 2014-11-27 | — | — | US | disclosed |
| US-8889181-B2 | Immunostimulatory compositions comprising liposome-encapsulated oligonucleotides and epitopes | INDUSTRY ACADEMIC COOPERATION FOUNDATION, HALLYM UNIVERSITY (KR) | 2014-11-18 | — | — | US | disclosed |
| US-20140302112-A1 | BONE MATRIX COMPOSITIONS AND METHODS | WARSAW ORTHOPEDIC INC (US) | 2014-10-09 | — | — | US | disclosed |
| US-20140255506-A1 | OSTEOINDUCTIVE DEMINERALIZED CANCELLOUS BONE | WARSAW ORTHOPEDIC, INC. (US) | 2014-09-11 | — | — | US | disclosed |
| US-20140219992-A1 | Metal Sensitive Mutants of Matrix Metalloproteases and uses thereof | PALADINI RUDOLPH D (US) | 2014-08-07 | — | — | US | disclosed |
| US-20140206597-A1 | Opioid Prodrugs with Heterocyclic Linkers | 3I, LP | 2014-07-24 | — | — | US | disclosed |
| US-8759354-B2 | Pharmaceutical composition comprising pyrazine derivative, and method of using pyrazine derivative in combination | TOYAMA CHEMICAL CO., LTD. (JP) | 2014-06-24 | — | — | US | disclosed |
| US-8758792-B2 | Bone matrix compositions and methods | WARSAW ORTHOPEDIC, INC. (US) | 2014-06-24 | — | — | US | disclosed |
| US-20140161771-A1 | RECOMBINANT INFLUENZA VIRUSES AND CONSTRUCTS AND USES THEREOF | UNIVERSITY OF MARYLAND, COLLEGE PARK | 2014-06-12 | — | — | US | disclosed |
| WO-2013106937-A9 | 3' EQUATORIAL-FLUORINE-SUBSTITUTED NEURAMINIDASE INHIBITOR COMPOUNDS, COMPOSITIONS AND METHODS FOR THE USE THEREOF AS ANTI-VIRALS | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2014-05-30 | — | — | WO | disclosed |
| US-8734525-B2 | Osteoinductive demineralized cancellous bone | WARSAW ORTHOPEDIC, INC. (US) | 2014-05-27 | — | — | US | disclosed |
| US-20140121152-A1 | Active Agent Prodrugs with Heterocyclic Linkers | SIGNATURE THERAPEUTICS, INC. (US) | 2014-05-01 | — | — | US | disclosed |
| EP-2722054-A1 | Methods and compositions for oral administration of proteins | Oramed Pharmaceuticals Inc. (IL) | 2014-04-23 | — | — | EP | disclosed |
| US-20140065239-A9 | OSTEOINDUCTIVE DEMINERALIZED CANCELLOUS BONE | WARSAW ORTHOPEDIC, INC. | 2014-03-06 | — | — | US | disclosed |
| EP-2702388-A1 | SAMPLE CONTAINERS ADAPTED FOR ACOUSTIC EJECTIONS AND SAMPLE PRESERVATION AND METHODS THEREOF | Labcyte Inc. (US) | 2014-03-05 | — | — | EP | disclosed |
| US-20140037743-A1 | MICROENCAPSULATED BIOACTIVE AGENTS FOR ORAL DELIVERY AND METHODS OF USE THEREOF | DELIVRX, INC. (US) | 2014-02-06 | — | — | US | disclosed |
| EP-2683394-A2 | ACTIVE AGENT PRODRUGS WITH HETEROCYCLIC LINKERS | Signature Therapeutics, Inc. (US) | 2014-01-15 | — | — | EP | disclosed |
| US-20130230552-A1 | INFLUENZA VIRUSES WITH MUTANT PB2 GENE SEGMENT AS LIVE ATTENUATED VACCINES | WARF - WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2013-09-05 | — | — | US | disclosed |
| US-20130210701-A1 | Compositions Comprising Enzyme-Cleavable Opioid Prodrugs and Inhibitors Thereof | SIGNATURE THERAPEUTICS, INC. (US) | 2013-08-15 | — | — | US | disclosed |
| US-20130210854-A1 | Compositions Comprising Enzyme-Cleavable Prodrugs of Active Agents and Inhibitors Thereof | SIGNATURE THERAPEUTICS, INC. (US) | 2013-08-15 | — | — | US | disclosed |
| US-20130209406-A1 | RECOMBINANT RNA VIRUSES AND USES THEREOF | NIH-DEITR | 2013-08-15 | — | — | US | disclosed |
| US-20130195939-A1 | METHODS AND COMPOSITIONS FOR ORAL ADMINISTRATION OF EXENATIDE | ORAMED LTD. (IL) | 2013-08-01 | — | — | US | disclosed |
| WO-2013106937-A1 | 3' EQUATORIAL-FLUORINE-SUBSTITUTED NEURAMINIDASE INHIBITOR COMPOUNDS, COMPOSITIONS AND METHODS FOR THE USE THEREOF AS ANTI-VIRALS | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2013-07-25 | — | — | WO | disclosed |
| US-20130136777-A1 | Bone Matrix Compositions and Methods | WARSAW ORTHOPEDIC, INC. (US) | 2013-05-30 | — | — | US | disclosed |
| WO-2013067309-A1 | METHODS AND COMPOSITIONS FOR ORAL ADMINISTRATION OF MELANOCORTIN RECEPTOR AGONIST COMPOUNDS | XION PHARMACEUTICAL CORPORATION (US) | 2013-05-10 | — | — | WO | disclosed |
| US-20130109042-A1 | SAMPLE CONTAINERS ADAPTED FOR ACOUSTIC EJECTIONS AND SAMPLE PRESERVATION AND METHODS THEREOF | LABCYTE INC. (US) | 2013-05-02 | — | — | US | disclosed |
| US-8426150-B2 | Process for differential polypeptides detection and uses thereof | LI RONGXIU (CN) | 2013-04-23 | — | — | US | disclosed |
| US-8404451-B2 | Mass spectrometric methods and products | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2013-03-26 | — | — | US | disclosed |
| US-20130064792-A1 | THERAPY FOR INFLUENZA LIKE ILLNESS | SYNAIRGEN RESEARCH LIMITED (GB) | 2013-03-14 | — | — | US | disclosed |
| US-20130059914-A1 | Compositions Comprising Enzyme-Cleavable Amphetamine Prodrugs and Inhibitors Thereof | SIGNATURE THERAPEUTICS, INC. (US) | 2013-03-07 | — | — | US | disclosed |
| EP-2560490-A1 | COMPOSITIONS COMPRISING ENZYME-CLEAVABLE PRODRUGS OF ACTIVE AGENTS AND INHIBITORS THEREOF | Signature Therapeutics, Inc. (US) | 2013-02-27 | — | — | EP | disclosed |
| EP-2560486-A1 | COMPOSITIONS COMPRISING ENZYME-CLEAVABLE AMPHETAMINE PRODRUGS AND INHIBITORS THEREOF | Signature Therapeutics, Inc. (US) | 2013-02-27 | — | — | EP | disclosed |
| EP-2560489-A1 | COMPOSITIONS COMPRISING ENZYME-CLEAVABLE OPIOID PRODRUGS AND INHIBITORS THEREOF | Signature Therapeutics, Inc. (US) | 2013-02-27 | — | — | EP | disclosed |
| US-8357384-B2 | Bone matrix compositions and methods | WARSAW ORTHOPEDIC, INC. (US) | 2013-01-22 | — | — | US | disclosed |
| US-20130011428-A1 | NOVEL STREPTOCOCCUS PNEUMONIAE OPEN READING FRAMES ENCODING POLYPEPTIDE ANTIGENS AND USES THEREOF | WYETH HOLDINGS CORPORATION (US) | 2013-01-10 | — | — | US | disclosed |
| US-8333985-B2 | Non-glycerol stabilized bone graft | WARSAW ORTHOPEDIC, INC. (US) | 2012-12-18 | — | — | US | disclosed |
| US-20120295834-A1 | Opioid Prodrugs with Heterocyclic Linkers | 3I, LP | 2012-11-22 | — | — | US | disclosed |
| WO-2012149314-A1 | SAMPLE CONTAINERS ADAPTED FOR ACOUSTIC EJECTIONS AND SAMPLE PRESERVATION AND METHODS THEREOF | LABCYTE INC. (US) | 2012-11-01 | — | — | WO | disclosed |
| US-8299219-B2 | Polypeptides, polynucleotides encoding same, antibodies thereagainst and methods of using same for diagnosing and treating cancer and skeletal disorders | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2012-10-30 | — | — | US | disclosed |
| EP-2509595-A1 | INHIBITORS OF HEMOPOIETIC CELL KINASE (P59-HCK) AND THEIR USE IN THE TREATMENT OF INFLUENZA INFECTION | Respivert Limited (GB) | 2012-10-17 | — | — | EP | disclosed |
| US-20120244120-A1 | INHIBITORS OF HEMOPOIETIC CELL KINASE (P59-HCK) AND THEIR USE IN THE TREATMENT OF INFLUENZA INFECTION | RESPIVERT LTD. (GB) | 2012-09-27 | — | — | US | disclosed |
| US-20120232066-A1 | COMPOSITIONS FOR REDUCING RISK OF ADVERSE EVENTS CAUSED BY DRUG-DRUG INTERACTIONS | SIGNATURE THERAPEUTICS, INC. | 2012-09-13 | — | — | US | disclosed |
| WO-2012122412-A2 | COMPOSITIONS FOR REDUCING RISK OF ADVERSE EVENTS CAUSED BY DRUG-DRUG INTERACTIONS | SIGNATURE THERAPEUTICS, INC. (US) | 2012-09-13 | — | — | WO | disclosed |
| WO-2012122422-A2 | ACTIVE AGENT PRODRUGS WITH HETEROCYCLIC LINKERS | SIGNATURE THERAPEUTICS, INC. (US) | 2012-09-13 | — | — | WO | disclosed |
| WO-2012122420-A2 | OPIOID PRODRUGS WITH HETEROCYCLIC LINKERS | PHARMACOFORE, INC. (US) | 2012-09-13 | — | — | WO | disclosed |
| EP-1942960-B1 | METHODS FOR PRODUCING BONE MATRIX COMPOSITION | WARSAW ORTHOPEDIC INC (US) | 2012-08-29 | — | — | EP | disclosed |
| EP-2490703-A1 | HERBAL COMPOSITION COMPRISING GINGER AND GOLDENROD FOR THE TREATMENT OF COLD AND FLU | Biopharmacopae Inc. (CA) | 2012-08-29 | — | — | EP | disclosed |
| US-8241642-B2 | Streptococcus pneumoniae open reading frames encoding polypeptide antigens and uses thereof | WYETH HOLDINGS CORPORATION (US) | 2012-08-14 | — | — | US | disclosed |
| US-20120201911-A1 | HERBAL COMPOSITION COMPRISING GINGER AND GOLDENROD FOR THE TREATMENT OF COLD AND FLU | BIOPHARMACOPAE INC. (CA) | 2012-08-09 | — | — | US | disclosed |
| US-20120142069-A1 | INTERPENETRATING BIOMATERIAL MATRICES AND USES THEREOF | NORTHWESTERN UNIVERSITY (US) | 2012-06-07 | — | — | US | disclosed |
| US-20120135443-A1 | Rapid Bed-Side Measurement of Neutrophil Elastase Activity in Biological Fluids | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED | 2012-05-31 | — | — | US | disclosed |
| US-20120114746-A1 | Immunostimulatory Compositions Comprising Liposome-Encapsulated Oligonucleotides and Epitopes | INDUSTRY ACADEMIC COOPERATION FOUNDATION, HALLYM UNIVERSITY (KR) | 2012-05-10 | — | — | US | disclosed |
| EP-2446049-A2 | RAPID BED-SIDE MEASUREMENT OF NEUTROPHIL ELASTASE ACTIVITY IN BIOLOGICAL FLUIDS | University of Florida Research Foundation, Incorporated (US) | 2012-05-02 | — | — | EP | disclosed |
| US-8163523-B2 | Cell-based systems for producing influenza vaccines | FLUGEN, INC. (US) | 2012-04-24 | — | — | US | disclosed |
| US-20120088251-A1 | MASS SPECTROMETRIC METHODS AND PRODUCTS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2012-04-12 | — | — | US | disclosed |
| US-20120064044-A1 | METHODS OF TREATING EDEMA RELATED TO ISCHEMIA-REPERFUSION | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL | 2012-03-15 | — | — | US | disclosed |
| US-20120040966-A1 | ANTI-VIRAL COMPOUNDS, TREATMENT, AND ASSAY | SOUTHERN RESEARCH INSTITUTE OFFICE OF COMMERCIALIZATION AND INTELLECTUAL PROP (US) | 2012-02-16 | — | — | US | disclosed |
| EP-2416651-A1 | METHODS OF TREATING EDEMA RELATED TO ISCHEMIA-REPERFUSION | The University of North Carolina At Chapel Hill (US) | 2012-02-15 | — | — | EP | disclosed |
| EP-2403447-A1 | MICROENCAPSULATED BIOACTIVE AGENTS FOR ORAL DELIVERY AND METHODS OF USE THEREOF | DelivRx, Inc. (US) | 2012-01-11 | — | — | EP | disclosed |
| CN-102307580-A | Anti-viral compounds, treatment and assay | SOUTHERN RES INST | 2012-01-04 | — | — | CN | disclosed |
| EP-2400029-A2 | Methods for cyclic nucleotide determination | Promega Corporation (US) | 2011-12-28 | — | — | EP | disclosed |
| EP-2392667-A2 | Assay for phosphodiesterases | Promega Corporation (US) | 2011-12-07 | — | — | EP | disclosed |
| EP-2381944-A1 | ANTI-VIRAL COMPOUNDS, TREATMENT, AND ASSAY | Southern Research Institute (US) | 2011-11-02 | — | — | EP | disclosed |
| WO-2011133348-A1 | COMPOSITIONS COMPRISING ENZYME-CLEAVABLE AMPHETAMINE PRODRUGS AND INHIBITORS THEREOF | PHARMACOFORE, INC. (US) | 2011-10-27 | — | — | WO | disclosed |
| WO-2011133150-A1 | COMPOSITIONS COMPRISING ENZYME-CLEAVABLE PRODRUGS OF ACTIVE AGENTS AND INHIBITORS THEREOF | PHARMACOFORE, INC. (US) | 2011-10-27 | — | — | WO | disclosed |
| WO-2011133149-A1 | COMPOSITIONS COMPRISING ENZYME-CLEAVABLE OPIOID PRODRUGS AND INHIBITORS THEREOF | PHARMACOFORE, INC. (US) | 2011-10-27 | — | — | WO | disclosed |
| US-20110262355-A1 | COMPOSITIONS COMPRISING ENZYME-CLEAVABLE OPIOID PRODRUGS AND INHIBITORS THEREOF | SIGNATURE THERAPEUTICS, INC. | 2011-10-27 | — | — | US | disclosed |
| US-20110262359-A1 | COMPOSITIONS COMPRISING ENZYME-CLEAVABLE PRODRUGS OF ACTIVE AGENTS AND INHIBITORS THEREOF | SIGNATURE THERAPEUTICS, INC. | 2011-10-27 | — | — | US | disclosed |
| EP-2142934-B1 | PRION ASSAY | NOVARTIS AG (CH) | 2011-10-26 | — | — | EP | disclosed |
| EP-1963366-B1 | METHODS FOR CYCLIC NUCLEOTIDE DETERMINATION | PROMEGA CORP (US) | 2011-09-14 | — | — | EP | disclosed |
| US-20110190216-A1 | MATERIALS AND METHODS FOR TREATMENT OF SPINAL MUSCULAR ATROPHY AND TAXANE-INDUCED PERIPHERAL NEUROPATHY (TIPN) | FLORIDA STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2011-08-04 | — | — | US | disclosed |
| US-20110177593-A1 | LOW RIGIDITY GELS FOR MSC GROWTH MODULATION | MAKOTO FUNAKI (US) | 2011-07-21 | — | — | US | disclosed |
| US-20110150761-A1 | POLYPEPTIDES, POLYNUCLEOTIDES ENCODING SAME, ANTIBODIES THEREAGAINST AND METHODS OF USING SAME FOR DIAGNOSING AND TREATING CANCER AND SKELETAL DISORDERS | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2011-06-23 | — | — | US | disclosed |
| US-20110150925-A1 | CELL-BASED SYSTEMS FOR PRODUCING INFLUENZA VACCINES | FLUGEN, INC. (US) | 2011-06-23 | — | — | US | disclosed |
| WO-2011070368-A1 | ANTIVIRAL USE OF UREA COMPOUNDS | RESPIVERT LIMITED (GB) | 2011-06-16 | — | — | WO | disclosed |
| US-20110142800-A1 | METHODS AND COMPOSITIONS FOR ORAL ADMINISTRATION OF PROTEINS | ORAMED LTD. (IL) | 2011-06-16 | — | — | US | disclosed |
| WO-2011070369-A1 | INHIBITORS OF HEMOPOIETIC CELL KINASE (P59-HCK) AND THEIR USE IN THE TREATMENT OF INFLUENZA INFECTION | RESPIVERT LIMITED (GB) | 2011-06-16 | — | — | WO | disclosed |
| EP-2331072-A1 | METHODS AND COMPOSITIONS FOR ORAL ADMINISTRATION OF PROTEINS | Oramed Ltd. (IL) | 2011-06-15 | — | — | EP | disclosed |
| US-7959941-B2 | demineralized bone matrix and an excipient, for repairing bone defects caused by injury, disease, wounds, surgery; osteoinductive factors including transforming growth factor, or bone morphogenic proteins | WARSAW ORTHOPEDIC, INC. (US) | 2011-06-14 | — | — | US | disclosed |
| US-20110129821-A1 | METHODS FOR CYCLIC NUCLEOTIDE DETERMINATION | PROMEGA CORPORATION (US) | 2011-06-02 | — | — | US | disclosed |
| WO-2011047473-A1 | HERBAL COMPOSITION COMPRISING GINGER AND GOLDENROD FOR THE TREATMENT OF COLD AND FLU | BIOPHARMACOPAE INC. (CA) | 2011-04-28 | — | — | WO | disclosed |
| US-7931906-B2 | Vero cell-based influenza virus strains and vaccines | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2011-04-26 | — | — | US | disclosed |
| US-7919602-B2 | Polypeptides, polynucleotides encoding same, antibodies thereagainst and methods of using same for diagnosing and treating cancer and skeletal disorders | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2011-04-05 | — | — | US | disclosed |
| EP-2300031-A2 | METHODS AND COMPOSITIONS FOR ORAL ADMINISTRATION OF EXENATIDE | Oramed Ltd. (IL) | 2011-03-30 | — | — | EP | disclosed |
| EP-2296701-A1 | CELL-BASED SYSTEMS FOR PRODUCING INFLUENZA VACCINES | Flugen, Inc. (US) | 2011-03-23 | — | — | EP | disclosed |
| EP-2295088-A1 | Improved bone graft | Osteotech, Inc., (US) | 2011-03-16 | — | — | EP | disclosed |
| US-20110059896-A1 | USE OF FURIN CONVERTASE INHIBITORS IN THE TREATMENT OF FIBROSIS AND SCARRING | RENOVO LIMITED | 2011-03-10 | — | — | US | disclosed |
| US-20110046053-A1 | METHODS AND COMPOSITIONS FOR ORAL ADMINISTRATION OF EXENATIDE | ORAMED LTD. (IL) | 2011-02-24 | — | — | US | disclosed |
| US-20110027771-A1 | METHODS AND COMPOSITIONS FOR CELL STABILIZATION | ARTEMIS HEALTH, INC. (US) | 2011-02-03 | — | — | US | disclosed |
| WO-2011014741-A1 | METHODS AND COMPOSITIONS FOR CELL STABILIZATION | ARTEMIS HEALTH, INC. (US) | 2011-02-03 | — | — | WO | disclosed |
| EP-2279244-A2 | METHODS AND COMPOSITIONS FOR ORAL ADMINISTRATION OF PROTEINS | Oramed Ltd. (IL) | 2011-02-02 | — | — | EP | disclosed |
| US-20110020836-A1 | PROCESS FOR DIFFERENTIAL POLYPEPTIDES DETECTION AND USES THEREOF | LI RONGXIU | 2011-01-27 | — | — | US | disclosed |
| EP-2278013-A1 | Streptococcus pneumoniae open reading frames encoding polypeptide antigens and uses thereof | Wyeth Holdings Corporation (US) | 2011-01-26 | — | — | EP | disclosed |
| EP-2277897-A1 | Streptococcus pneumoniae open reading frames encoding polypeptide antigens and uses thereof | Wyeth Holdings Corporation (US) | 2011-01-26 | — | — | EP | disclosed |
| US-20110014247-A1 | METHODS AND COMPOSITIONS FOR ORAL ADMINISTRATION OF PROTEINS | ORAMED LTD. (IL) | 2011-01-20 | — | — | US | disclosed |
| WO-2011005974-A2 | INTERPENETRATING BIOMATERIAL MATRICES AND USES THEREOF | NORTHWESTERN UNIVERSITY (US) | 2011-01-13 | — | — | WO | disclosed |
| WO-2010151878-A2 | RAPID BED-SIDE MEASUREMENT OF NEUTROPHIL ELASTASE ACTIVITY IN BIOLOGICAL FLUIDS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2010-12-29 | — | — | WO | disclosed |
| EP-2261241-A1 | STREPTOCOCCUS PNEUMONIAE OPEN READING FRAMES ENCODING POLYPEPTIDE ANTIGENS AND USES THEREOF | Wyeth Holdings Corporation (US) | 2010-12-15 | — | — | EP | disclosed |
| CN-101914557-A | Expression and purification of humanized chymotrypsin | INST BIOPHYSICS CN ACAD SCI | 2010-12-15 | — | — | CN | disclosed |
| EP-2258842-A1 | Streptococcus pneumoniae open reading frames encoding polypeptide antigens and uses thereof | Wyeth Holdings Corporation (US) | 2010-12-08 | — | — | EP | disclosed |
| EP-2258718-A1 | Streptococcus pneumoniae open reading frames encoding polypeptide antigens and uses thereof | Wyeth Holdings Corporation (US) | 2010-12-08 | — | — | EP | disclosed |
| WO-2010133173-A1 | PROCESS FOR DIFFERENTIAL POLYPEPTIDES DETECTION AND USES THEREOF | LI RONGXIU (CN) | 2010-11-25 | — | — | WO | disclosed |
| US-20100291598-A1 | PRION ELISA | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2010-11-18 | — | — | US | disclosed |
| US-7833725-B2 | Mass spectrometric methods and products | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2010-11-16 | — | — | US | disclosed |
| US-7829296-B2 | Kinesin polypeptides, polynucleotides encoding same and compositions and methods of using same | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2010-11-09 | — | — | US | disclosed |
| WO-2010118334-A1 | METHODS OF TREATING EDEMA RELATED TO ISCHEMIA-REPERFUSION | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2010-10-14 | — | — | WO | disclosed |
| WO-2010102198-A1 | MICROENCAPSULATED BIOACTIVE AGENTS FOR ORAL DELIVERY AND METHODS OF USE THEREOF | TAMARISK TECHNOLOGIES, L.L.C. (US) | 2010-09-10 | — | — | WO | disclosed |
| US-20100226995-A1 | MICROENCAPSULATED BIOACTIVE AGENTS FOR ORAL DELIVERY AND METHODS OF USE THEREOF | TAMARISK TECHNOLOGIES GROUP, LLC | 2010-09-09 | — | — | US | disclosed |
| US-20100227399-A1 | SOFT GEL SYSTEMS IN MODULATING STEM CELL DEVELOPMENT | MAKOTO FUNAKI (US) | 2010-09-09 | — | — | US | disclosed |
| US-20100221288-A1 | NOVEL STREPTOCOCCUS PNEUMONIAE OPEN READING FRAMES ENCODING POLYPEPTIDE ANTIGENS AND USES THEREOF | WYETH HOLDINGS CORPORATION (US) | 2010-09-02 | — | — | US | disclosed |
| US-20100209417-A1 | Antibody Treatment of Alzheimer's and Related Diseases | TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA | 2010-08-19 | — | — | US | disclosed |
| US-7771731-B2 | Altered fibronectin-binding protein of Staphylococcus aureus | WYETH LLC (US) | 2010-08-10 | — | — | US | disclosed |
| US-20100196934-A1 | PRION ASSAY | NOVARTIS AG (CH) | 2010-08-05 | — | — | US | disclosed |
| US-20100184657-A1 | METHODS OF TREATING EPITHELIAL LESIONS OUTSIDE THE STOMACH AND INTESTINES | PODOLSKY DANIEL K | 2010-07-22 | — | — | US | disclosed |
| WO-2010078229-A1 | ANTI-VIRAL COMPOUNDS, TREATMENT, AND ASSAY | SOUTHERN RESEARCH INSTITUTE (US) | 2010-07-08 | — | — | WO | disclosed |
| US-7700562-B2 | Use of —furin—“convertase” inhibitors in the treatment of fibrosis and scarring | RENOVO LIMITED (GB) | 2010-04-20 | — | — | US | disclosed |
| US-20100087447-A1 | PHARMACEUTICAL COMPOSITION COMPRISING PYRAZINE DERIVATIVE, AND METHOD OF USING PYRAZINE DERIVATIVE IN COMBINATION | TOYAMA CHEMICAL CO., LTD. (JP) | 2010-04-08 | — | — | US | disclosed |
| EP-2167147-A2 | BONE MATRIX COMPOSITIONS AND METHODS | Osteotech, Inc., (US) | 2010-03-31 | — | — | EP | disclosed |
| WO-2010020978-A1 | METHODS AND COMPOSITIONS FOR ORAL ADMINISTRATION OF PROTEINS | ORAMED PHARMACEUTICALS LTD (IL) | 2010-02-25 | — | — | WO | disclosed |
| US-20100021499-A1 | CELL-BASED SYSTEMS FOR PRODUCING INFLUENZA VACCINES | FLUGEN, INC. | 2010-01-28 | — | — | US | disclosed |
| US-20100009378-A1 | Mass Spectrometric Methods and Products | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2010-01-14 | — | — | US | disclosed |
| EP-2142934-A1 | PRION ASSAY | Novartis Ag (CH) | 2010-01-13 | — | — | EP | disclosed |
| EP-2140272-A1 | PRION ELISA | Novartis Ag (CH) | 2010-01-06 | — | — | EP | disclosed |
| WO-2009152181-A1 | CELL-BASED SYSTEMS FOR PRODUCING INFLUENZA VACCINES | FLUGEN, INC. (US) | 2009-12-17 | — | — | WO | disclosed |
| US-RE41028-E1 | Treating eye disorders intestinal trefoil proteins | THE GENERAL HOSPITAL CORPORATION (US) | 2009-12-01 | — | — | US | disclosed |
| EP-2123276-A1 | PHARMACEUTICAL COMPOSITION COMPRISING PYRAZINE DERIVATIVE, AND METHOD OF USING PYRAZINE DERIVATIVE IN COMBINATION | Toyama Chemical Co., Ltd. (JP) | 2009-11-25 | — | — | EP | disclosed |
| US-20090280123-A1 | Kinesin polypeptides, polynucleotides encoding same and compositions and methods of using same | RAMOT AT TEL AVIV UNIVERSITY LTD. (IL) | 2009-11-12 | — | — | US | disclosed |
| WO-2009136392-A2 | METHODS AND COMPOSITIONS FOR ORAL ADMINISTRATION OF EXENATIDE | ORAMED PHARMACEUTICALS, LTD. (IL) | 2009-11-12 | — | — | WO | disclosed |
| WO-2009118722-A2 | METHODS AND COMPOSITIONS FOR ORAL ADMINISTRATION OF PROTEINS | ORAMED PHARMACEUTICALS, INC. (IL) | 2009-10-01 | — | — | WO | disclosed |
| US-20090227513-A1 | TREATING EYE DISORDERS USING INTESTINAL TREFOIL PROTEINS | PODOLSKY DANIEL K | 2009-09-10 | — | — | US | disclosed |
| US-20090155378-A1 | OSTEOINDUCTIVE DEMINERALIZED CANCELLOUS BONE | BEHNAM KEYVAN | 2009-06-18 | — | — | US | disclosed |
| US-20090136518-A1 | Compositions and methods to reduce mutagenesis | THE SCRIPPS RESEARCH INSTITUTE (US) | 2009-05-28 | — | — | US | disclosed |
| US-7538194-B2 | Genes encoding several poly (ADP-ribose) glycohydrolase (PARG) enzymes, the proteins and fragments thereof, and antibodies immunoreactive therewith | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2009-05-26 | — | — | US | disclosed |
| US-20090130173-A1 | BONE MATRIX COMPOSITIONS AND METHODS | WARSAW ORTHOPEDIC, INC. | 2009-05-21 | — | — | US | disclosed |
| US-20090123537-A1 | ORAL DOSAGE FORM OF CEFTRIAXONE AND METHODS OF USE | PHERMACEUTICA | 2009-05-14 | — | — | US | disclosed |
| EP-1963366-A4 | METHODS FOR CYCLIC NUCLEOTIDE DETERMINATION | PROMEGA CORP (US) | 2009-05-06 | — | — | EP | disclosed |
| US-20090074804-A1 | VERO CELL-BASED INFLUENZA VIRUS STRAINS AND VACCINES | NATIONAL HEALTH RESEARCH INSTITUTE (AN INSTITUTION OF TAIWAN, R.O.C.) (TW) | 2009-03-19 | — | — | US | disclosed |
| US-20090075839-A1 | Novel streptococcus pneumoniae open reading frames encoding polypeptide antigents and uses thereof | WYETH HOLDINGS CORPORATION (US) | 2009-03-19 | — | — | US | disclosed |
| US-20090053248-A1 | Compositions and methods for transepithelial molecular transport | THOMAS JEFFERSON UNIVERSITY (US) | 2009-02-26 | — | — | US | disclosed |
| EP-1951892-A4 | ANTIBODY TREATMENT OF ALZHEIMER'S AND RELATED DISEASES | UNIV PENNSYLVANIA (US) | 2009-01-14 | — | — | EP | disclosed |
| WO-2008157495-A2 | BONE MATRIX COMPOSITIONS AND METHODS | OSTEOTECH, INC. (US) | 2008-12-24 | — | — | WO | disclosed |
| WO-2008157492-A2 | OSTEOINDUCTIVE DEMINERALIZED CANCELLOUS BONE | OSTEOTECH, INC. (US) | 2008-12-24 | — | — | WO | disclosed |
| US-7455840-B2 | Compositions and methods to reduce mutagenesis | THE SCRIPPS RESEARCH INSTITUTE (US) | 2008-11-25 | — | — | US | disclosed |
| WO-2008124098-A1 | PRION ASSAY | NOVARTIS AG (CH) | 2008-10-16 | — | — | WO | disclosed |
| WO-2008124100-A1 | PRION ELISA | NOVARTIS AG (CH) | 2008-10-16 | — | — | WO | disclosed |
| EP-1963366-A2 | METHODS FOR CYCLIC NUCLEOTIDE DETERMINATION | PROMEGA CORPORATION (US) | 2008-09-03 | — | — | EP | disclosed |
| US-20080195024-A1 | Treating Disorders Associated with Inflammation | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2008-08-14 | — | — | US | disclosed |
| EP-1951892-A1 | ANTIBODY TREATMENT OF ALZHEIMER'S AND RELATED DISEASES | The Trustees of the University of Pennsylvania (US) | 2008-08-06 | — | — | EP | disclosed |
| EP-1942960-A2 | BONE MATRIX COMPOSITIONS AND METHODS | Osteotech, Inc., (US) | 2008-07-16 | — | — | EP | disclosed |
| EP-1933862-A2 | METHODS AND COMPOSITIONS FOR ORAL ADMINISTRATION OF PROTEINS | Oramed Pharmaceuticals Inc. (IL) | 2008-06-25 | — | — | EP | disclosed |
| US-20080145392-A1 | Bone Graft | WARSAW ORTHOPEDIC, INC. | 2008-06-19 | — | — | US | disclosed |
| EP-1875922-A2 | Intestinal trefoil proteins | The General Hospital Corporation (US) | 2008-01-09 | — | — | EP | disclosed |
| US-20070231788-A1 | Method for In Vitro Assay of Demineralized Bone Matrix | WARSAW ORTHOPEDIC, INC. | 2007-10-04 | — | — | US | disclosed |
| US-20070178158-A1 | Stabilized bone graft | WARSAW ORTHOPEDIC, INC. | 2007-08-02 | — | — | US | disclosed |
| US-20070172896-A1 | Methods for cyclic nucleotide determination | PROMEGA CORPORATION (US) | 2007-07-26 | — | — | US | disclosed |
| US-20070136833-A1 | Genes encoding several poly (ADP-RIBOSE) glycohydrolase (PARG) enzymes, the proteins and fragments thereof, and antibodies immunoreactive therewith | NIADYNE, INC. | 2007-06-14 | — | — | US | disclosed |
| WO-2007067557-A2 | METHODS FOR CYCLIC NUCLEOTIDE DETERMINATION | PROMEGA CORPORATION (US) | 2007-06-14 | — | — | WO | disclosed |
| EP-0954330-B1 | INTESTINAL TREFOIL PROTEINS | GEN HOSPITAL CORP (US) | 2007-06-13 | — | — | EP | disclosed |
| WO-2007062088-A1 | ANTIBODY TREATMENT OF ALZHEIMER'S AND RELATED DISEASES | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2007-05-31 | — | — | WO | disclosed |
| US-20070110820-A1 | Bone Matrix Compositions and Methods | WARSAW ORTHOPEDIC, INC. | 2007-05-17 | — | — | US | disclosed |
| WO-2007053850-A2 | BONE MATRIX COMPOSITIONS AND METHODS | OSTEOTECH, INC. (US) | 2007-05-10 | — | — | WO | disclosed |
| US-20070098756-A1 | Bone Matrix Compositions and Methods | WARSAW ORTHOPEDIC, INC. | 2007-05-03 | — | — | US | disclosed |
| US-20070087957-A1 | Methods and compositions for oral administration of proteins | ORAMED PHARMACEUTICALS INC. (IL) | 2007-04-19 | — | — | US | disclosed |
| US-7202333-B1 | DNA encoding IgE Receptor α-subunit or fragment thereof | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2007-04-10 | — | — | US | disclosed |
| EP-1572868-A4 | NOVEL STREPTOCOCCUS PNEUMONIAE OPEN READING FRAMES ENCODING POLYPEPTIDE ANTIGENS AND USES THEREOF | WYETH CORP (US) | 2007-04-04 | — | — | EP | disclosed |
| EP-1766416-A1 | USE OF STANDARDS FOR MONITORING ALTERATIONS OF PEPTIDE AND PROTEIN SAMPLES | DIGILAB BioVisioN GmbH (DE) | 2007-03-28 | — | — | EP | disclosed |
| WO-2007029238-A2 | METHODS AND COMPOSITIONS FOR ORAL ADMINISTRATION OF PROTEINS | ORAMED PHARMACEUTICALS, INC. (IL) | 2007-03-15 | — | — | WO | disclosed |
| US-20070026478-A1 | Hemiasterlin affinity probes and their uses | WYETH (US) | 2007-02-01 | — | — | US | disclosed |
| US-7169989-B2 | Process for creating a 3-dimensional configuration on a substrate | BEN GURION UNIVERSITY OF THE NEGEV, RESEARCH AND DEVELOPMENT AUTHORITY (IL) | 2007-01-30 | — | — | US | disclosed |
| US-7163691-B2 | Bone graft | OSTEOTECH, INC. (US) | 2007-01-16 | — | — | US | disclosed |
| US-20070009433-A1 | 14094, a novel human trypsin family member and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. | 2007-01-11 | — | — | US | disclosed |
| US-20060292153-A1 | Polypeptides, polynucleotides encoding same, antibodies thereagainst and methods of using same for diagnosing and treating cancer and skeletal disorders | RAMOT AT TEL AVIV UNIVERSITY LTD. (IL) | 2006-12-28 | — | — | US | disclosed |
| US-7150988-B2 | Controlling proteolytic action in natural rubber latex | ROCHE DIAGNOSTICS OPERATIONS, INC. (US) | 2006-12-19 | — | — | US | disclosed |
| WO-2006114788-A1 | KINESIN POLYPEPTIDES, POLYNUCLEOTIDES ENCODING SAME AND COMPOSITIONS AND METHODS OF USING SAME | RAMOT AT TEL AVIV UNIVERSITY LTD. (IL) | 2006-11-02 | — | — | WO | disclosed |
| EP-1708651-A1 | STABILIZED BONE GRAFT | Osteotech, Inc., (US) | 2006-10-11 | — | — | EP | disclosed |
| EP-1689852-A2 | COMPOSITIONS AND METHODS TO REDUCE MUTAGENESIS | The Scripps Research Institute (US) | 2006-08-16 | — | — | EP | disclosed |
| US-7071004-B1 | 14094, a novel human trypsin family member and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2006-07-04 | — | — | US | disclosed |
| WO-2006063810-A1 | CONTROLLING PROTEOLYTIC ACTION NATURAL RUBBER LATEX | ROCHE DIAGNOSTICS GMBH (DE) | 2006-06-22 | — | — | WO | disclosed |
| US-20060111302-A1 | Compositions and methods to reduce mutagenesis | THE SCRIPPS RESEARCH INSTITUTE & ACHAOGEN, INC. | 2006-05-25 | — | — | US | disclosed |
| US-20060052309-A1 | Use of convertase inhibitors in the treatment of fibrosis and scarring | RENOVO LIMITED (GB) | 2006-03-09 | — | — | US | disclosed |
| EP-1619503-A1 | Use of standards for monitoring alterations of peptide and protein samples | BioVisioN AG (DE) | 2006-01-25 | — | — | EP | disclosed |
| WO-2006005622-A1 | USE OF STANDARDS FOR MONITORING ALTERATIONS OF PEPTIDE AND PROTEIN SAMPLES | DIGILAB BIOVISION GMBH (DE) | 2006-01-19 | — | — | WO | disclosed |
| US-20060008854-A1 | Method of determining time of death | SABUCEDO ALBERTO J | 2006-01-12 | — | — | US | disclosed |
| EP-1531859-A4 | COMPOSITIONS AND METHODS FOR TRANSEPITHELIAL MOLECULAR TRANSPORT | UNIV JEFFERSON (US) | 2005-12-07 | — | — | EP | disclosed |
| US-20050227933-A1 | Treatment of bacterial induced diseases using DNA methyl transferase inhibitors | BENKOVIC STEPHEN J | 2005-10-13 | — | — | US | disclosed |
| US-20050220901-A1 | Methods of pharmaceutical separation from plants | HUTTENBAUER SAMUEL JR | 2005-10-06 | — | — | US | disclosed |
| EP-1572868-A2 | NOVEL STREPTOCOCCUS PNEUMONIAE OPEN READING FRAMES ENCODING POLYPEPTIDE ANTIGENS AND USES THEREOF | Wyeth Holdings Corporation (US) | 2005-09-14 | — | — | EP | disclosed |
| WO-2005080569-A1 | POLYPEPTIDES, POLYNUCLEOTIDES ENCODING SAME, ANTIBODIES THEREAGAINST AND METHODS OF USING SAME FOR DIAGNOSING AND TREATING CANCER AND SKELETAL DISORDERS | RAMOT AT TEL AVIV UNIVERSITY LTD. (IL) | 2005-09-01 | — | — | WO | disclosed |
| WO-2005072656-A1 | STABILIZED BONE GRAFT | OSTEOTECH, INC. (US) | 2005-08-11 | — | — | WO | disclosed |
| US-20050176050-A1 | Genes encoding several poly(ADP-ribose) glycohydrolase (PARG) enzymes, the proteins and fragments thereof, and antibodies immunoreactive therewith | JACOBSON MYRON K (US) | 2005-08-11 | — | — | US | disclosed |
| EP-1556080-A1 | USE OF CONVERTASE INHIBITORS IN THE TREATMENT OF FIBROSIS AND SCARRING | Renovo Limited (GB) | 2005-07-27 | — | — | EP | disclosed |
| WO-2005056754-A2 | COMPOSITIONS AND METHODS TO REDUCE MUTAGENESIS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2005-06-23 | — | — | WO | disclosed |
| US-20050118673-A1 | Process for creating a 3-dimensional configuration on a substrate | BEN GURION UNIVERSITY OF THE NEGEV, RESEARCH AND DEVELOPMENT AUTHORITY (IL) | 2005-06-02 | — | — | US | disclosed |
| EP-1531859-A1 | COMPOSITIONS AND METHODS FOR TRANSEPITHELIAL MOLECULAR TRANSPORT | THOMAS JEFFERSON UNIVERSITY (US) | 2005-05-25 | — | — | EP | disclosed |
| US-6887983-B2 | Purified 20 kDA presenilin 2 C-terminal fragment and methods of screening for compounds that inhibit proteolysis of presenilin 2 | THE GENERAL HOSPITAL CORPORATION (US) | 2005-05-03 | — | — | US | disclosed |
| WO-2003101484-A9 | COMPOSITIONS AND METHODS FOR TRANSEPITHELIAL MOLECULAR TRANSPORT | UNIV JEFFERSON (US) | 2005-03-17 | — | — | WO | disclosed |
| US-6843996-B1 | Immunogenic composition comprising an influenza virus with a temperature sensitive PB2 mutation | MEDIMMUNE VACCINES, INC. (US) | 2005-01-18 | — | — | US | disclosed |
| US-20040259833-A1 | DNA methyl transferase inhibitors | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2004-12-23 | — | — | US | disclosed |
| EP-0822983-A4 | APOPAIN | MERCK & CO INC (US) | 2004-12-15 | — | — | EP | disclosed |
| EP-1434608-A2 | IMPROVED BONE GRAFT | Osteotech, Inc. (US) | 2004-07-07 | — | — | EP | disclosed |
| EP-1420021-A1 | DNA Methyltransferase inhibitors | The Penn State Research Foundation (US) | 2004-05-19 | — | — | EP | disclosed |
| EP-1287355-B1 | METHODS AND COMPOUNDS FOR INFLUENCING BETA3 INTEGRIN-DEPENDENT INTRACELLULAR PROCESSES | PROCORDE GMBH (DE) | 2004-04-21 | — | — | EP | disclosed |
| WO-2004009113-A1 | USE OF CONVERTASE INHIBITORS IN THE TREATMENT OF FIBROSIS AND SCARRING | RENOVO LIMITED (GB) | 2004-01-29 | — | — | WO | disclosed |
| US-20040013687-A1 | Compositions and methods for transepithelial molecular transport | THOMAS JEFFERSON UNIVERSITY | 2004-01-22 | — | — | US | disclosed |
| WO-2003101484-A1 | COMPOSITIONS AND METHODS FOR TRANSEPITHELIAL MOLECULAR TRANSPORT | THOMAS JEFFERSON UNIVERSITY (US) | 2003-12-11 | — | — | WO | disclosed |
| US-20030225250-A1 | Intestinal trefoil proteins | PODOLSKY DANIEL K (US) | 2003-12-04 | — | — | US | disclosed |
| US-20030186886-A1 | Treating eye disorders using intestinal trefoil proteins | GENERAL HOSPITAL CORPORATION, THE | 2003-10-02 | — | — | US | disclosed |
| US-20030143258-A1 | Bone graft | WARSAW ORTHOPEDIC, INC. | 2003-07-31 | — | — | US | disclosed |
| US-20030134797-A1 | Treating eye disorders using intestinal trefoil proteins | PODOLSKY DANIEL K (US) | 2003-07-17 | — | — | US | disclosed |
| US-20030088057-A1 | PEPTIDE SUBSTRATES PHOSPHORYLATED BY P21-ACTIVAGED PROTEIN KINASE STATEMENT REGARDING FEDERALLY SPONSORED REASEARCH OR DEVELOPMENT | TRAUGH JOLINDA A (US) | 2003-05-08 | — | — | US | disclosed |
| WO-2003030956-A2 | IMPROVED BONE GRAFT | OSTEOTECH, INC. (US) | 2003-04-17 | — | — | WO | disclosed |
| US-20030044868-A1 | Method for detecting prion proteins in tissue samples | PARADIGM GENETICS, INC. | 2003-03-06 | — | — | US | disclosed |
| EP-1287355-A2 | METHODS AND COMPOUNDS FOR INFLUENCING $G(B)3 INTEGRIN-DEPENDENT INTRACELLULAR PROCESSES | Procorde GmbH (DE) | 2003-03-05 | — | — | EP | disclosed |
| US-6525018-B1 | Intestinal trefoil factor (ITF), spasmolytic peptide (SP), pS2; treatment of a disruption of the corneal epithelium | THE GENERAL HOSPITAL CORP. | 2003-02-25 | — | — | US | disclosed |
| EP-1280923-A2 | 14094, A HUMAN TRYPSIN FAMILY MEMBER AND USES THEREOF | Millennium Pharmaceuticals, Inc. (US) | 2003-02-05 | — | — | EP | disclosed |
| US-20020197741-A1 | Method of determining time of death | SABUCEDO ALBERT J (US) | 2002-12-26 | — | — | US | disclosed |
| WO-2002083855-A2 | NOVEL STREPTOCOCCUS PNEUMONIAE OPEN READING FRAMES ENCODING POLYPEPTIDE ANTIGENS AND USES THEREOF | WYETH HOLDINGS CORPORATION (US) | 2002-10-24 | — | — | WO | disclosed |
| US-20020086444-A1 | PURIFIED 20 KDA PRESENILIN 2 C-TERMINAL FRAGMENT AND METHODS OF SCREENING FOR COMPOUNDS THAT INHIBIT PROTEOLYSIS OF PRESENILIN 2 | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2002-07-04 | — | — | US | disclosed |
| US-20020052483-A1 | Intestinal trefoil proteins | THE GENERAL HOSPITAL CORPORATION, MASSACHUSETTS CORPORATION | 2002-05-02 | — | — | US | disclosed |
| WO-2001094613-A2 | METHODS AND COMPOUNDS FOR INFLUENCING BETA3 INTEGRIN-DEPENDENT INTRACELLULAR PROCESSES | PROCORDE GMBH (DE) | 2001-12-13 | — | — | WO | disclosed |
| WO-2001083781-A2 | 14094, A NOVEL HUMAN TRYPSIN FAMILY MEMBER AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2001-11-08 | — | — | WO | disclosed |
| US-6228989-B1 | AMINO ACID SEQUENCE OF PEPTIDE; FOR ANALYZING SPECIFIC PROTEIN KINASE ACTIVITY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2001-05-08 | — | — | US | disclosed |
| US-6221840-B1 | PEPTIDES USEFUL FOR TREATMENT OF DISORDERS OF THE DIGESTIVE SYSTEM. | THE GENERAL HOSPITAL CORPORATION | 2001-04-24 | — | — | US | disclosed |
| US-6090391-A | GENETIC ENGINEERING | AVIRON (US) | 2000-07-18 | — | — | US | disclosed |
| EP-0514830-B1 | Use of a herpes protease | ARCH DEV CORP (US) | 2000-05-03 | — | — | EP | disclosed |
| EP-0977776-A2 | A PURIFIED 20 kDa PRESENILIN 2 C-TERMINAL FRAGMENT AND METHODS OF SCREENING FOR COMPOUNDS THAT INHIBIT PROTEOLYSIS OF PRESENILIN 2 | THE GENERAL HOSPITAL CORPORATION (US) | 2000-02-09 | — | — | EP | disclosed |
| US-5976859-A | COMPOSITIONS FOR CLEANING AND WASHING PURPOSES. | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 1999-11-02 | — | — | US | disclosed |
| WO-1998047917-A9 | A PURIFIED 20 kDa PRESENILIN 2 C-TERMINAL FRAGMENT AND METHODS OF SCREENING FOR COMPOUNDS THAT INHIBIT PROTEOLYSIS OF PRESENILIN 2 | GEN HOSPITAL CORP (US) | 1999-05-14 | — | — | WO | disclosed |
| EP-0394302-B1 | DNA ENCODING IgE RECEPTOR ALPHA-SUBUNIT OR FRAGMENT THEREOF | HARVARD COLLEGE (US) | 1999-03-03 | — | — | EP | disclosed |
| US-5861477-A | POLYPEPTIDES AS TISSUE PLASMINOGEN ACTIVATOR | ATASSI M ZOUHAIR (US) | 1999-01-19 | — | — | US | disclosed |
| WO-1998047917-A2 | A PURIFIED 20 kDa PRESENILIN 2 C-TERMINAL FRAGMENT AND METHODS OF SCREENING FOR COMPOUNDS THAT INHIBIT PROTEOLYSIS OF PRESENILIN 2 | THE GENERAL HOSPITAL CORPORATION (US) | 1998-10-29 | — | — | WO | disclosed |
| US-5759834-A | SYNTHETIC POLYPEPTIDE AS CATALYST | ATASSI M ZOUHAIR (US) | 1998-06-02 | — | — | US | disclosed |
| WO-1998021319-A1 | DETERGENT-STABLE MICROBIAL PROTEASE | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 1998-05-22 | — | — | WO | disclosed |
| EP-0822983-A1 | APOPAIN | Merck & Co., Inc. (US) | 1998-02-11 | — | — | EP | disclosed |
| EP-0504335-B1 | A FIBRONECTIN BINDING PEPTIDE | ALFA LAVAL AGRI INT (SE) | 1997-12-10 | — | — | EP | disclosed |
| US-5602102-A | ADMINSTERING IN TREATMENT OF ORGAN ALLOGRAFT REJECTION | BOARD OF REGENTS, THE UNIV. OF TX SYSTEM (US) | 1997-02-11 | — | — | US | disclosed |
| US-5578477-A | SCREENING FOR ANTICANCER DRUGS, SOURCE OF PURE ENZYME | ARCH DEVELOPMENT CORPORATION (US) | 1996-11-26 | — | — | US | disclosed |
| WO-1996033268-A1 | APOPAIN | MERCK & CO., INC. (US) | 1996-10-24 | — | — | WO | disclosed |
| US-5478727-A | Identifying enzyme inhibitor; detecting viral infections | ARCH DEVELOPMENT CORPORATION (US) | 1995-12-26 | — | — | US | disclosed |
| US-5440014-A | For vaccines, wound treatment, blocking protein receptors, medical diagnosis | HOEOEK MAGNUS (US) | 1995-08-08 | — | — | US | disclosed |
| US-5403824-A | Administering a opioid, opioid-degrading enzyme inhibitor or enkephalin secretagogues or mixtures thereof; side effect reduction | THE PROCTER & GAMBLE COMPANY (US) | 1995-04-04 | — | — | US | disclosed |
| US-5385732-A | For treatment of vascular disorders, longer circulating half-lives, slower clearance rates | GENENTECH, INC. (US) | 1995-01-31 | — | — | US | disclosed |
| WO-1994028018-A2 | SYNTHETIC STERICALLY-CONSTRAINED CATALYSTS | ATASSI ZOUHAIR (US) | 1994-12-08 | — | — | WO | disclosed |
| JP-H06321804-A | CALCITONIN NASOANTRAL PREPARATION | TEIJIN LTD | 1994-11-22 | — | — | JP | disclosed |
| WO-1994021242-A1 | METHODS FOR THE TREATMENT OF OSTEOPOROSIS | THE PROCTER & GAMBLE COMPANY (US) | 1994-09-29 | — | — | WO | disclosed |
| EP-0424405-B1 | VARIANTS OF PLASMINOGEN ACTIVATORS AND PROCESSES FOR THEIR PRODUCTION | GENENTECH INC (US) | 1994-09-14 | — | — | EP | disclosed |
| EP-0347781-B1 | Mini-proinsulin, its oroduction and use | HOECHST AG (DE) | 1994-02-16 | — | — | EP | disclosed |
| WO-1993024634-A1 | DIPEPTIDYL PEPTIDASE-I, CLONING IT, AND THERAPEUTIC AGENTS CONTAINING INHIBITORS THEREOF | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1993-12-09 | — | — | WO | disclosed |
| EP-0225177-B1 | DNA SEQUENCE CODING FOR HUMAN TISSUE PLASMINOGEN ACTIVATOR | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1993-09-01 | — | — | EP | disclosed |
| EP-0535241-A1 | NOVEL LEUCINE AMINOPEPTIDASE | SUNTORY LIMITED (JP) | 1993-04-07 | — | — | EP | disclosed |
| EP-0514830-A2 | Methods and compositions of a preparation and use of a herpes protease | ARCH DEVELOPMENT CORPORATION (US) | 1992-11-25 | — | — | EP | disclosed |
| EP-0504335-A1 | A FIBRONECTIN BINDING PEPTIDE | ALFA-LAVAL AGRI INTERNATIONAL AB (SE) | 1992-09-23 | — | — | EP | disclosed |
| WO-1992002555-A1 | A FIBRONECTIN BINDING PEPTIDE | ALFA-LAVAL AGRI INTERNATIONAL AKTIEBOLAG (SE) | 1992-02-20 | — | — | WO | disclosed |
| EP-0428603-A4 | CYTOTOXIC AGENT AGAINST SPECIFIC VIRUS INFECTION | US COMMERCE (US) | 1991-11-13 | — | — | EP | disclosed |
| WO-1991015512-A2 | HIV ENVELOPE POLYPEPTIDES | GENENTECH, INC. (US) | 1991-10-17 | — | — | WO | disclosed |
| EP-0394302-A4 | DNA ENCODING IGE RECEPTOR -G(A)-SUBUNIT OR FRAGMENT THEREOF | — | 1991-09-11 | — | — | EP | disclosed |
| EP-0428603-A1 | CYTOTOXIC AGENT AGAINST SPECIFIC VIRUS INFECTION | THE UNITED STATES OF AMERICA as represented by the Secretary UNITED STATES DEPARTMENT OF COMMERCE (US) | 1991-05-29 | — | — | EP | disclosed |
| EP-0424405-A1 | VARIANTS OF PLASMINOGEN ACTIVATORS AND PROCESSES FOR THEIR PRODUCTION. | GENENTECH INC (US) | 1991-05-02 | — | — | EP | disclosed |
| EP-0394302-A1 | DNA ENCODING IgE RECEPTOR $g(a)-SUBUNIT OR FRAGMENT THEREOF | THE PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 1990-10-31 | — | — | EP | disclosed |
| US-4962035-A | DNA encoding IgE receptor alpha-subunit or fragment thereof | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 1990-10-09 | — | — | US | disclosed |
| WO-1990001035-A1 | CYTOTOXIC AGENT AGAINST SPECIFIC VIRUS INFECTION | THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, UNITED STATES DEPARTMENT OF COMMERCE (US) | 1990-02-08 | — | — | WO | disclosed |
| EP-0347781-A2 | Mini-proinsulin, its oroduction and use | HOECHST AKTIENGESELLSCHAFT (DE) | 1989-12-27 | — | — | EP | disclosed |
| WO-1989011531-A1 | VARIANTS OF PLASMINOGEN ACTIVATORS AND PROCESSES FOR THEIR PRODUCTION | GENENTECH, INC. (US) | 1989-11-30 | — | — | WO | disclosed |
| WO-1989005352-A1 | DNA ENCODING IgE RECEPTOR alpha-SUBUNIT OR FRAGMENT THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 1989-06-15 | — | — | WO | disclosed |
| EP-0225177-A2 | DNA sequence coding for human tissue plasminogen activator | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1987-06-10 | — | — | EP | disclosed |
| US-4657739-A | COMPOSITE BIOLOGICAL LAYER OF FIBERS AND PARTICLES BOUND TO ACTIVE MATERIAL | FUJI PHOTO FILM CO., LTD. | 1987-04-14 | — | — | US | disclosed |
| EP-0119622-A2 | Integral element for biological reaction and process for the preparation thereof | FUJI PHOTO FILM CO., LTD. (JP) | 1984-09-26 | — | — | EP | disclosed |
| EP-0119622-A2 | Integral element for biological reaction and process for the preparation thereof | FUJI PHOTO FILM CO., LTD. (JP) | 1984-09-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (50 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11179355-B2 | Compositions comprising enzyme-cleavable amphetamine prodrugs and inhibitors thereof | ACHE, COMT, CES2 | MMP9 243/4885TDP1 119/4885MMP2 97/4885 |
| US-20200093817-A1 | OPIOID COMPOSITIONS RESISTANT TO OVERDOSE AND ABUSE | OPRM1, OPRK1, OPRD1 | MMP9 521/4885TDP1 1454/4885MMP2 538/4885 |
| US-20250186555-A1 | FORMULATIONS COMPRISING ACID-NEUTRALIZING POLYMER FOR ORAL ADMINISTRATION OF GLUCAGON-LIKE PEPTIDE-2 | IAPP, GCG, GLP1R | MMP9 1307/4885TDP1 4355/4885MMP2 1570/4885 |
| US-20170165223-A1 | 3' Equatorial-Fluorine-Substituted Neuraminidase Inhibitor Compounds, Compositions and Methods for the Use Thereof as Anti-Virals | NEU3, NEU1, NEU2 | MMP9 277/4885TDP1 1548/4885MMP2 238/4885 |
| US-20250388655-A1 | PEPTIDE CONSTRUCT HAVING A PROTEASE-CLEAVABLE LINKER | VIP, PREP, PEPD | MMP9 206/4885TDP1 3037/4885MMP2 218/4885 |
| US-20140121152-A1 | Active Agent Prodrugs with Heterocyclic Linkers | PEPD, SI, PREP | MMP9 150/4885TDP1 794/4885MMP2 8/4885 |
| US-20250186554-A1 | FORMULATIONS COMPRISING ACID-NEUTRALIZING POLYMER FOR ORAL ADMINISTRATION OF GLUCAGON-LIKE PEPTIDE-1 AND ANALOGS THEREOF | GLP1R, GIPR, GCGR | MMP9 1945/4885TDP1 3659/4885MMP2 2386/4885 |
| US-20260124281-A1 | FORMULATIONS COMPRISING ACID-NEUTRALIZING POLYMER FOR ORAL ADMINISTRATION OF PARATHYROID HORMONE | PTH1R, FGF23, PTMS | MMP9 1073/4885TDP1 4228/4885MMP2 2302/4885 |
| US-20260077011-A1 | INTEGRIN INHIBITORS AS THERAPY FOR OBESITY DISORDERS | ITGAL, ITGB1, ITGAM | MMP9 126/4885TDP1 4253/4885MMP2 663/4885 |
| US-20120295834-A1 | Opioid Prodrugs with Heterocyclic Linkers | OPRK1, OPRM1, PREP | MMP9 269/4885TDP1 1019/4885MMP2 26/4885 |
| US-20130210701-A1 | Compositions Comprising Enzyme-Cleavable Opioid Prodrugs and Inhibitors Thereof | ACHE, OPRM1, DNPEP | MMP9 61/4885TDP1 558/4885MMP2 52/4885 |
| US-20070026478-A1 | Hemiasterlin affinity probes and their uses | TUBA1C, TUBB1, TUBB | MMP9 4872/4885TDP1 2963/4885MMP2 4512/4885 |
| US-20240415936-A1 | FORMULATIONS FOR ORAL ADMINISTRATION OF ACTIVE AGENTS | NNT, NQO1, NAMPT | MMP9 873/4885TDP1 4409/4885MMP2 1997/4885 |
| US-20180000830-A1 | INHIBITORS OF HEMOPOIETIC CELL KINASE (P-59-HCK) AND THEIR USE IN THE TREATMENT OF INFLUENZA INFECTION | HCK, CDK9, PHKG1 | MMP9 1782/4885TDP1 1993/4885MMP2 2621/4885 |
| US-12559544-B2 | Antibodies that bind human metapneumovirus fusion protein and their use | FCGR3B, FCGR2A, FCGR1A | MMP9 3651/4885TDP1 2567/4885MMP2 2500/4885 |
| US-20260071218-A1 | Oral Delivery of Antisense Conjugates Targeting PCSK9 | PCSK9, ALPI, SLC10A2 | MMP9 664/4885TDP1 2676/4885MMP2 1050/4885 |
| US-20220054479-A1 | OPIOID COMPOSITIONS RESISTANT TO OVERDOSE AND ABUSE | OPRM1, OPRK1, OPRD1 | MMP9 521/4885TDP1 1454/4885MMP2 538/4885 |
| US-20180085366-A1 | OPIOID COMPOSITIONS RESISTANT TO OVERDOSE AND ABUSE | OPRM1, OPRK1, OPRD1 | MMP9 521/4885TDP1 1454/4885MMP2 538/4885 |
| US-20120040966-A1 | ANTI-VIRAL COMPOUNDS, TREATMENT, AND ASSAY | ZC3HAV1, OAT, MAVS | MMP9 1488/4885TDP1 1333/4885MMP2 354/4885 |
| US-20240181020-A1 | TREATMENT OF HYPOPARATHYROIDISM | PTH1R, PTMS, CYP24A1 | MMP9 2418/4885TDP1 3861/4885MMP2 1282/4885 |
| US-20180021272-A1 | FORMULATIONS FOR ORAL ADMINISTRATION OF ACTIVE AGENTS | SI, CTSC, CTRC | MMP9 139/4885TDP1 3568/4885MMP2 112/4885 |
| US-20100087447-A1 | PHARMACEUTICAL COMPOSITION COMPRISING PYRAZINE DERIVATIVE, AND METHOD OF USING PYRAZINE DERIVATIVE IN COMBINATION | PEPD, NEU1, NEU2 | MMP9 2269/4885TDP1 1609/4885MMP2 1343/4885 |
| US-20160235694-A1 | Compositions Comprising Enzyme-Cleavable Amphetamine Prodrugs and Inhibitors Thereof | ACHE, COMT, CES2 | MMP9 243/4885TDP1 119/4885MMP2 97/4885 |
| US-20120244120-A1 | INHIBITORS OF HEMOPOIETIC CELL KINASE (P59-HCK) AND THEIR USE IN THE TREATMENT OF INFLUENZA INFECTION | HCK, CDK9, TTK | MMP9 1730/4885TDP1 2083/4885MMP2 2615/4885 |
| US-20180050096-A1 | TREATMENT OF HYPOPARATHYROIDISM | PTH1R, PTMS, CYP24A1 | MMP9 2418/4885TDP1 3861/4885MMP2 1282/4885 |
| US-20240207409-A1 | ORAL DELIVERY OF OLIGONUCLEOTIDES | RNGTT, RNMT, SRRT | MMP9 2738/4885TDP1 792/4885MMP2 2759/4885 |
| US-20110262359-A1 | COMPOSITIONS COMPRISING ENZYME-CLEAVABLE PRODRUGS OF ACTIVE AGENTS AND INHIBITORS THEREOF | PEPD, TMPRSS15, ADAM17 | MMP9 54/4885TDP1 229/4885MMP2 37/4885 |
| US-20140350095-A1 | 3' Equatorial-Fluorine-Substituted Neuraminidase Inhibitor Compounds, Compositions and Methods for the Use Thereof as Anti-Virals | NEU3, NEU1, NEU2 | MMP9 277/4885TDP1 1548/4885MMP2 238/4885 |
| US-20140206597-A1 | Opioid Prodrugs with Heterocyclic Linkers | OPRK1, OPRM1, PREP | MMP9 269/4885TDP1 1019/4885MMP2 26/4885 |
| US-20240067965-A1 | ORAL DELIVERY OF ANTISENSE CONJUGATES TARGETING PCSK9 | PCSK9, SCD5, PCSK7 | MMP9 1547/4885TDP1 1921/4885MMP2 1699/4885 |
| US-20130210854-A1 | Compositions Comprising Enzyme-Cleavable Prodrugs of Active Agents and Inhibitors Thereof | PEPD, TMPRSS15, ADAM17 | MMP9 54/4885TDP1 229/4885MMP2 37/4885 |
| US-20250186559-A1 | FORMULATIONS COMPRISING ACID-NEUTRALIZING POLYMER FOR ORAL ADMINISTRATION OF PARATHYROID HORMONE | PTH1R, FGF23, ALPP | MMP9 440/4885TDP1 4051/4885MMP2 596/4885 |
| US-20090136518-A1 | Compositions and methods to reduce mutagenesis | OGG1, DNMT3A, APOBEC3G | MMP9 3920/4885TDP1 430/4885MMP2 4260/4885 |
| US-20160326208-A1 | 5'-SUBSTITUTED NUCLEOSIDE COMPOUNDS | NT5C3B, MCL1, NSUN2 | MMP9 2044/4885TDP1 749/4885MMP2 2871/4885 |
| US-12239691-B2 | Formulations for oral administration of active agents | NNT, NQO1, NAMPT | MMP9 873/4885TDP1 4409/4885MMP2 1997/4885 |
| US-20180028622-A1 | TREATMENT OF OSTEOPOROSIS | PTH1R, PTMS, SOST | MMP9 1016/4885TDP1 4544/4885MMP2 1234/4885 |
| US-20180036234-A1 | TREATMENT OF BONE FRACTURES AND DEFECTS | PTH1R, SOST, PTMS | MMP9 845/4885TDP1 3978/4885MMP2 373/4885 |
| US-20060111302-A1 | Compositions and methods to reduce mutagenesis | OGG1, DNMT3A, APOBEC3G | MMP9 3920/4885TDP1 430/4885MMP2 4260/4885 |
| US-20160002291-A1 | Active Agent Prodrugs with Heterocyclic Linkers | PEPD, SI, PREP | MMP9 150/4885TDP1 794/4885MMP2 8/4885 |
| US-10335406-B2 | Opioid compositions resistant to overdose and abuse | OPRM1, OPRK1, OPRD1 | MMP9 521/4885TDP1 1454/4885MMP2 538/4885 |
| US-20120232066-A1 | COMPOSITIONS FOR REDUCING RISK OF ADVERSE EVENTS CAUSED BY DRUG-DRUG INTERACTIONS | CYP2C19, CYP3A5, CYP3A4 | MMP9 404/4885TDP1 573/4885MMP2 875/4885 |
| US-20250186558-A1 | FORMULATIONS COMPRISING ACID-NEUTRALIZING POLYMER FOR ORAL ADMINISTRATION OF ACTIVE AGENTS | ASAH2, SLC10A2, FABP2 | MMP9 550/4885TDP1 3304/4885MMP2 765/4885 |
| US-20110262355-A1 | COMPOSITIONS COMPRISING ENZYME-CLEAVABLE OPIOID PRODRUGS AND INHIBITORS THEREOF | ACHE, OPRM1, DNPEP | MMP9 61/4885TDP1 558/4885MMP2 52/4885 |
| US-20050227933-A1 | Treatment of bacterial induced diseases using DNA methyl transferase inhibitors | DNMT1, TPMT, GNMT | MMP9 1132/4885TDP1 179/4885MMP2 993/4885 |
| US-20030088057-A1 | PEPTIDE SUBSTRATES PHOSPHORYLATED BY P21-ACTIVAGED PROTEIN KINASE STATEMENT REGARDING FEDERALLY SPONSORED REASEARCH OR DEVELOPMENT | PAK1, PAK2, PAK6 | MMP9 3974/4885TDP1 1533/4885MMP2 2818/4885 |
| US-20220213476-A1 | ORAL DELIVERY OF ANTISENSE CONJUGATES TARGETING PCSK9 | PCSK9, SCD5, PCSK7 | MMP9 1547/4885TDP1 1921/4885MMP2 1699/4885 |
| US-20220380761-A1 | ORAL DELIVERY OF OLIGONUCLEOTIDES | RNGTT, RNMT, SRRT | MMP9 2738/4885TDP1 792/4885MMP2 2759/4885 |
| US-12291708-B2 | Oral delivery of antisense conjugates targeting PCSK9 | PCSK9, SCD5, PCSK7 | MMP9 1547/4885TDP1 1921/4885MMP2 1699/4885 |
| US-20190209657-A1 | FORMULATIONS FOR ORAL ADMINISTRATION OF ACTIVE AGENTS | NNT, NQO1, NAMPT | MMP9 873/4885TDP1 4409/4885MMP2 1997/4885 |
| US-20130059914-A1 | Compositions Comprising Enzyme-Cleavable Amphetamine Prodrugs and Inhibitors Thereof | ACHE, COMT, CES2 | MMP9 243/4885TDP1 119/4885MMP2 97/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.